

CURRICULUM VITAE
of
SUSAN C. FAGAN
Jowdy Professor / Assistant Dean
(August, 2020)

Addresses

Work	Permanent
Professor of Pharmacy	339 Railroad Ave, Unit 344
College of Pharmacy	North Augusta, SC 29841
University of Georgia	
HM-116; Augusta University Campus	
1120 15 th Street	
Augusta, GA 30912-2450	

Citizenship United States of America

Board Certification Pharmacotherapy, 1992 (BPS)
 Recertification, 1999 (BPS)
 Recertification, 2007 (BPS)
 Recertification, 2014 (BPS)

Professional Experience

2013-pres Distinguished Research Professor, University of Georgia

2013-pres Assistant Dean and Director, Center for Pharmacy and Experimental
 Therapeutics, Medical College of Georgia, Georgia Regents University

2008–pres Jowdy Professor of Pharmacy Care

2017 – 2019 Director of Interprofessional Education (Interim), College of Pharmacy,
 University of Georgia

2007-2017 Associate Head, Department of Clinical and Administrative Pharmacy

2007-pres Assistant Dean
 University of Georgia College of Pharmacy

2006-2007 Interim Head
 Department of Clinical and Administrative Pharmacy
 University of Georgia College of Pharmacy

2000-pres Adjunct Professor of Neurology
Medical College of Georgia

1999-pres Professor
Department of Clinical and Administrative Pharmacy
College of Pharmacy
University of Georgia

Research Pharmacist (WOC)
Neuroscience Service Line
VA Medical Center
Augusta, GA

1999 Professor of Pharmacy Practice
College of Pharmacy and AHP
Wayne State University

1997-1999 Associate Chair of Pharmacy Practice
College of Pharmacy and AHP
Wayne State University

1996- 1997: Interim Chair of Pharmacy Practice
College of Pharmacy and AHP
Wayne State University

1995-1996 : Associate Chair of Pharmacy Practice
College of Pharmacy and AHP
Wayne State University

1994-1998 : Chairman, Curriculum Committee
College of Pharmacy and AHP
Wayne State University

1993-1994: Visiting Professor
Department of Neurosciences
University of California, San Diego
(with J.A. Zivin, M.D., Ph.D.)

1992-1999: Associate Professor
College of Pharmacy
Wayne State University and

Manager, Pharmaceutical Research
Department of Pharmacy Services

Henry Ford Hospital

1990-1996: Consultant, Health Protection Branch,
Government of Canada, Review of New
Drug Submissions

1990-1992: Assistant Professor
College of Pharmacy
Wayne State University and

Manager, Division of Pharmaceutical Research
Department of Pharmacy Services
Henry Ford Hospital

1988-1989 : Chairman, Pharm.D. Program Committee
College of Pharmacy
Wayne State University
Detroit, MI

1986-1989 : Assistant Professor
College of Pharmacy
Wayne State University and

Coordinator, Education and Training,
Department of Pharmacy Services
Henry Ford Hospital

1984-1986 : Research Associate
Dent Neurologic Inst.
Buffalo, New York

1983-1984 : Research Assistant
Clinical Pharmacokinetics Laboratory
Millard Fillmore Hospital
Buffalo, New York

1980-1982 : Staff Pharmacist
Cochrane's Pharmacy
Wolfville, Nova Scotia
Canada

Education

1985 - 1986 : Presidential fellowship in Pharmaceutics
State University of New York at Buffalo

and Dent Neurologic Institute
Buffalo, New York

1984 - 1985 : Miles fellowship in Neuropharmacology
Dent Neurologic Institute
Buffalo, New York

1982 - 1984 : Doctor of Pharmacy
State University of New York at Buffalo
Buffalo, New York

1976 - 1980 : Bachelor of Sciences, Pharmacy - cum laude
College of Pharmacy
Dalhousie University
Halifax, Nova Scotia
Canada

Professional Affiliations

Member - American College of Clinical Pharmacy; 1984 - pres
Regent 8/96 - 8/99

Member - American Association of Colleges of Pharmacy; 1986 - pres

Member - National Stroke Association
Prevention Advisory Board: 12/00 – 1/04

Member - Stroke Council, American Heart Association: 1992 - pres

Awards

ACCP - BMS Central Nervous System Research Award - 1995-1996

Fellow of the American College of Clinical Pharmacy (FCCP) (1995)

Fellow of the Stroke Council, American Heart Association (1993)

Career Development Chair Award, Wayne State University (1993)

Gustavus A. Pfeiffer Faculty Development Fellowship Award, American Foundation for
Pharmaceutical Education (1993)

Teacher of the Year - Second Professional Year (B.S. curriculum); (1996-1997)

Teacher of the Year - Pharm.D. I ; (1997-1998)

Jowdy Professor of Pharmacy Care: (2008-pres)

Distinguished Research Professor; University of Georgia: (2013 – pres)

Women's Leadership Fellow; University of Georgia: (2015 – 2016)

Data Safety Monitoring Boards

Pfizer, Inc; Study A9541004; PDE5 inhibitor in Ischemic Stroke: 2010 – 2013 (stopped for futility in December, 2013)

Professional Offices

Pharmacy

Board of Regents; American College of Clinical Pharmacy; 1996 – 1999 (elected)
Executive Committee, American College of Clinical Pharmacy, 1997- 1999
Board of Directors, Pharmacotherapy; 1996 – 1999
Member-at-Large, American Pharmacists Association, Academy of Pharmaceutical Research and Science; Section on Clinical Sciences; 2003-2005 (elected)
Research Institute Board of Trustees, American College of Clinical Pharmacy; 2006-2009 (elected)
Chair (elected), ACCP Research Institute Board of Trustees; 2008-2009
Faculty, Focused Investigator Training (FIT) Program, ACCP; 2009 – present
Member (appointed), ACCP Research Institute Board of Trustees: 2011 - 2013
Board of Directors, Pharmacotherapy; 2013 – 2014 (appointed)

Stroke / AHA

Prevention Advisory Board, National Stroke Association; 2000 – 2007
Continuing Education Subcommittee, American Heart Association; 2002-2005
Member-at-Large, Leadership Committee, Stroke Council, American Heart Association; 2005-2007 (elected)
Professional Education Committee, American Heart Association, 2005-2008
Chair, Professional Education Committee, American Stroke Association, 2005-2008
National Stroke Association; Regional Meeting Program Committee: 2007
American Heart Association National Speakers Program – Scientific Advisory Board; 2007-2008
Leadership Committee, Stroke Council, American Heart Association, 2007-2008 (appointed)

NIH

Steering/Planning Committee/Faculty, NIH / NINDS Clinical Trials Course, University of Rochester, NY; 2007-2010
Invited Participant: 26th Princeton Conference on Cerebrovascular Disease (NIH-funded invitational conference), Houston, TX, March 27-30, 2008
Invited Participant: 27th Princeton Conference on Cerebrovascular Disease (NIH-funded invitational conference), Boston, MA, April 22-24, 2010

Charlie Norwood VA Medical Center

Member, Subcommittee on Research Safety: 2005 – 2010
Member, Research and Development Committee: 2005 – 2010
Chair, Subcommittee on Research Safety: 2007 – 2010
Chair, Research and Development Committee: 2010 – 2012
Alternate member, Institutional Animal Care and Use Committee (IACUC): 2015-2016
Member, Institutional Animal Care and Use Committee (IACUC): 2016 - present

Editorial Boards

Editorial Board, Journal of Stroke and Cerebrovascular Disease; 1996 - 2000
Section Editor, Journal of Informed Pharmacotherapy; 1999-2004
Editorial Board, Pharmacotherapy Self-Assessment Program (fourth edition); 1999-2002
Editorial Board, Annals of Pharmacotherapy; 2000 – 2008
Editorial Board, Pharmacotherapy; 2001 - 2015
Editorial Board, Pharmacotherapy Self-Assessment Program (fifth edition); 2002 – 2005
Editorial Board, Clotcare.com: 2007 – present
Editorial Board, Translational Stroke Research; 2011 - pres
Editorial Board, Stroke: 2012 - 2015

Study Sections

American Heart Association – National; Brain 1 Study Section; 2002 - 2006
NIH – NINDS Special Emphasis Panel: ZNS1 SRB-K (20); 2004
NIH – NINDS: ZRG1-BDCNL-90: Brain injury and neurovascular pathologies; 2005- 2006
ACCP Research Institute; CNS Investigator Development Award Panel; 2005
NIH – NINDS: NSD-K: Pilot Clinical trials; 2005 – 2007 (Standing Member)
NIH -NINDS: ZNS1 SRB-M (28); 2005
NIH – NINDS: ZNS1 SRB-M (30); 2005
NIH – NINDS: ZNS1K-44; 2006
NIH – NINDS: ZNS1 SRB G(20) Stroke SEP Review; 2007
NIH – NINDS: NSD-K: Clinical trials; 2008 – 2011 (Standing Member)
American Heart Association – National; Brain 2 Study Section; 2009
NIH-NINDS: NSD-C: Neurology C (ad hoc): October, 2011
NIH- NCATS: ZTR1 CI-9(01); Therapeutics Discovery X02 SEP; September, 2012
American Heart Association – National; Brain 3 Study Section; 2013
NIH-NINDS: ZNS1 SRB-E; US-China Collaborations; 2013
NIH-NINDS: ZNS1 SRB-E (58); Clinical Trials Methods Course – R25; January, 2014
NIH-NINDS: ZNS1SRBN06; EUREKA awards; June, 2014
MRC (UK): Neurosciences and Mental Health Board: Neurophysiology of systems; ad hoc: Nov-Dec, 2015
ACCP Research Institute: Clinical Research Challenge Review Panel; 2016
NIH-NINDS: NSD-A; June, 2014 – June 2018 (Standing Member)
NIH-NCATS: SEP: Bench Testing: February, 2018
American Heart Association Career Development Award Review Panel: March, 2018
NIH-NINDS: ZNS1-SRB-D (03); NINDS Stroke Preclinical Assessment Network (SPAN);

March, 2019

NIH CSR: BDCN-E (03): Brain injury and chronic neurodegeneration; October, 2019

NIH: NIH Director's New Innovator Award Review – 2020; November, 2019

NIH: ZRG1 – BDCN-L; Special Emphasis Panel, July, 2020

Publications

1. Chandler, R.F., **Fagan, S.C.** The family planning challenge Can Pharm J 1980;113:276-279
2. Gengo, F.M., **Fagan, S.C.**, Kinkel, W.R., McHugh, W.B. Serum concentrations of propranolol and migraine prophylaxis. Arch Neurol 1984; 41:1306-1307
3. **Fagan, S.C.**, Castellani, D.A., Gengo, F.M. Prostanoid concentrations in human CSF following acute ischemic brain infarction. Clin Exp Pharm Physiol 1986;13: 629-632
4. Gengo, F.M., **Fagan, S.C.**, Krol, G., Bernhard, H. Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls. Br J Clin Pharmacol 1987;23: 47-53
5. **Fagan, S.C.** and Gengo, F.M. Time course of changes in CSF Thromboxane B2 concentrations after experimental cerebral ischemia. Neurology 1987;37 (Suppl 1):249
6. **Fagan, S.C.**, Gengo, F.M., Bates, V., Levine, S.R., Kinkel, W.R. Effect of Nimodipine on blood pressure in human acute ischemic stroke. Stroke 1988; 19: 401-402
7. Gengo, F.M., **Fagan, S.C.**, dePadova, A., Miller, J.K., Kinkel, P.: The Effect of Beta-Blockers on Mental Performance in Older Hypertensive Patients. Arch Int Med 1988; 148:779-784
8. Gengo, F.M., **Fagan, S.C.**, Hopkins, L.N., Wagner, D., Schuster, D. : Nonlinear distribution of atenolol between serum and cerebrospinal fluid. Pharm Res 1989;6(3):248-251
9. **Fagan, S.C.**, McCormick, P.W., Diaz, F.G.: Hemodynamic vertebrobasilar insufficiency as an adverse effect of antihypertensive therapy. DICP Ann Pharmacother 1989;23:238-239
10. Ewing JR, Branch CA, Fagan SC, Helpert JA, Simkins RT, Butt SM, Welch KMA: Fluorocarbon-23 measure of cat cerebral blood flow by nuclear magnetic resonance. Stroke 1990;21:100-106
11. **Fagan SC**, Payne LW, Houtekier SC: Risk of cerebral hypoperfusion with antihypertensive therapy. DICP Ann Pharmacother 1989;23:957-962

12. Levine SR, **Fagan SC**, Pessin MS, Floberg J, Selwa JF, Vogel CM, Welch KMA: Accelerated intracranial occlusive disease, oral contraceptives and cigarette use. *Neurology* 1991;41:1893-1901
13. Branch CA, Ewing JR, **Fagan SC**, Goldberg DA, Welch KMA: Acute toxicity of a nuclear magnetic resonance cerebral blood flow indicator in cats. *Stroke* 1990;21:1172-1177
14. **Fagan SC**, Ewing JR, Levine SR, Teitjen GE, Ramadan NM, Welch KMA: Assessing the effects of antihypertensive medication on cerebral blood flow: Demonstration in internal carotid artery occlusion. *DICP Ann Pharmacother* 1991; 25:1299-1301
15. **Fagan SC** and Nacci N: Nimodipine and bradycardia in acute stroke - drug or disease ? *DICP Ann Pharmacother* 1991;25:247-9
16. Robert S, Miller AJ, **Fagan SC**: Ticlopidine : A new antiplatelet agent for cerebrovascular disease. *Pharmacother* 1991;11(4):317-325
17. **Fagan SC**, Bindlish V, Robert S, Steigerwalt SP, Ramadan NM: Transcranial doppler to evaluate the effects of antihypertensive medication on cerebral blood flow velocity. *J Clin Pharmacol* 1992;32:66-69
18. **Fagan SC**, Robert S, Zarowitz BJ: Brain attack - A new indication for thrombolysis ? *Ann Pharmacother* 1992;26:73-80
19. Jahns BE and **Fagan SC** : Antagonists of excitatory amino acids in acute stroke. *ACCP Report* 1991; 10(9):3
20. **Fagan SC**, Robert S, Ewing JR, Levine SR, Ramadan NM, Welch KMA : Cerebral blood flow changes with enalapril. *Pharmacotherapy* 1992;12:319-323
21. Patel RV, **Fagan SC**, Kertland HR, Jahns BE, Mlynarek M, Zarowitz BJ: Labetalol: Response and safety in critically ill hemorrhagic stroke patients. *Ann Pharmacother* 1993;27:180-181
22. **Fagan SC**, Kertland HR, Tietjen GE: Safety of combination aspirin and anticoagulation in acute ischemic stroke. *Ann Pharmacother* 1994;28:441-443
23. **Fagan SC**: Stroke management. *J Pharm Prac* 1993;VI(6):297-303
24. **Fagan SC**: Stroke: The injured brain. *U.S. Pharmacist* 1994; Feb.:44-68
25. Branch CA, Goldberg DA, Ewing JR, **Fagan SC**, Butt SM, Gayner J: Evaluation of the acute cardiac and central nervous system effects of the fluorocarbon trifluoromethane in

baboons. J Toxicol Environ Health 1994;Sep;43(1):25-35

26. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Liesen JCC, Buckley L, Cooper SM, Duncan H, Pillemer SR, Tuttleman M, Fowler SE ; for the **MIRA Trial Group**: Minocycline in Rheumatoid Arthritis. A 48-week, double-blind, placebo-controlled trial. Ann Int Med 1995;122:81-89

27. Bowes MP, Rothlein R, **Fagan SC**, Zivin JA: Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance the efficacy of thrombolytic therapy. Neurology 1995;45:815-819

28. **Fagan SC**, Rahill A, Balakrishnan G, Ewing JR, Branch CA, Brown GG: Neurotoxicity and physiologic effects of trifluoromethane in man. J Toxicology Environ Health 1995;45(2): 221-229

29. **Fagan SC**, Levine SR, Ewing JR, Ramadan NM, Welch KMA: Age and carotid artery occlusive disease are important determinants of the cerebral blood flow changes after antihypertensive therapy. Pharmacotherapy 1995;15:573-578

30. **The National Institute of Neurological Disorders and Stroke rt-TPA Stroke Study Group**: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587

31. Patel RV, Ramadan NM, Levine SR, Welch KMA, **Fagan SC**: The effects of ramipril and enalapril on cerebral blood flow in elderly patients with asymptomatic carotid artery occlusive disease. J Cardiovasc Pharmacol 1996; 28:48-52

32. Gidal BE, Wagner ML, Privitera MD, Dalmady-Israel C, Crismon ML, **Fagan SC**, Graves NM: Current developments in neurology, Part I: Advances in the pharmacotherapy of headache, epilepsy, and multiple sclerosis. Ann Pharmacother 1996;30:1272-1276

33. Gidal BE, Crismon ML, Wagner ML, **Fagan SC**, Privitera MD, Dalmady-Israel C, Graves NM: Current developments in neurology, Part II. Ann Pharmacother 1996; 30:1446-1451

34. Bowes MP, Zivin JA, Thomas GR, Thibodeaux H, **Fagan SC**: Acute hypertension, but not thrombolysis, increases the incidence and severity of cerebral hemorrhage in rabbits. Exp Neurol, 1996; 141(1):40-46

35. Chant C, **Fagan SC**, Aurora S, Gidal BE, Joseph R: Ticlopidine and aspirin and platelet function in smokers and nonsmokers. Ann Pharmacother 1997;31:290-293

36. Chase HC, **Fagan SC**, Slaughter RL: Rewarding volunteer faculty at a College of Pharmacy. Can J Hosp Pharm 1997;50:29-31

37. Dumo P, **Fagan SC**, Carhuapoma JR: Clinical commentary: Thrombolysis in acute ischemic stroke. *Am J Health System Pharm* 1997;54: 2213-2217
38. **The NINDS t-PA Stroke Study Group**: Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. *Stroke* 1997;28:2109-2118
39. **The NINDS t-PA Stroke Study Group**: Generalized efficacy of t-PA for Acute Stroke: Subgroup analysis of the NINDS t-PA Stroke Trial. *Stroke* 1997;28:2119-2125
40. Knight RA, Barker PB, **Fagan SC**, Li Y, Jacobs MA, Welch KMA: Prediction of impending hemorrhagic transformation in ischemic stroke using Magnetic Resonance Imaging. *Stroke* 1998;29:144-151
41. **Fagan SC**, Bowes MP, Lyden PD, Zivin JA: Acute hypertension promotes hemorrhagic infarction in a rabbit embolic stroke model. Effect of labetalol. *Exp Neurol* 1998;150:153-158
42. **Fagan SC**, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP, Kwiatkowski T, Frankel M, Walker MD and the NINDS rt-PA Stroke Study Group: Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. *Neurology* 1998;50:883-890
43. Brott TG, Lu M, Kothari R, **Fagan SC**, Frankel M, Grotta JC, Broderick J, Kwiatkowski T, Lewandowski C, Haley EC, Marler JR, Tilley BC: Hypertension and its treatment in the NINDS t-PA Stroke Study. *Stroke* 1998;29:1504-1509
44. Rahill A, Brown GG, **Fagan SC**, Ewing JR, Branch CA, Balakrishnan G : Neuropsychological dose effects of a Freon, trifluoromethane(FC-23), compared to N2O. *Neurotoxicology and Teratology* 1998;20:617-626.
45. **Fagan SC**, Rhoney DH: Countering the rising incidence of stroke. *American Druggist (Invited)* 1998; Oct.:64-71
46. **Fagan SC**, Garcia JH: Hemorrhagic transformation in focal cerebral ischemia: Effect of time to artery reopening and tissue plasminogen activator. *Pharmacotherapy* 1999;19:139-142
47. **Fagan SC**, Bowes MP, Berri S, Zivin JA: Combination therapy for acute ischemic stroke: A ray of hope. *J Stroke Cerebrovasc Dis*, 1999;8:359-367
48. Ng TMH, Kohli A, **Fagan SC**, Mohamed AE, Geiszt G: The effect of intravenous verapamil on cerebral hemodynamics in a migraine patient with hemiplegia. *Ann Pharmacother* 2000; 34 : 39-43

49. Brott TG, Grotta JC, Latchaw RE, Starkman S, Jauch E, Clark WM, **Fagan SC**, Hopkins LN: Stroke The First Hours. Consensus Statement. October, 2000; National Stroke Association
50. Hess DC, **Fagan SC**: Pharmacology and clinical experience with simvastatin. *Exp Opin in Pharmacother* 2001;2(1):153-163
51. **Fagan SC**: Hemorrhagic transformation after reperfusion therapy for acute ischemic stroke. *J Inform Pharmacother* (online) 2001;4:300-305
52. **Fagan S**. The International Stroke Trial: What "IS" the Best Therapy for Acute Ischaemic Stroke? *J Inform Pharmacother* (online) 2001;5:213-215.
53. Grotta JC, Welch KMA, **Fagan SC**, Lu M, Frankel MR, Brott T, Levine SR, Lyden PD and the NINDS rt-PA Stroke Study Group. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. *Stroke* 2001;32:661-668
54. Broderick J, Lu M, Jackson C, Pancioli A, Tilley BC, **Fagan SC**, Kothari R, Levine SR, Marler JR, Lyden PD, Haley EC, Brott TG, Grotta J and the NINDS rt-PA Stroke Study Group: Apolipoprotein E phenotype and the efficacy of tissue plasminogen activator in acute ischemic stroke. *Ann Neurol* 2001; 49:736-744
55. Sinclair SE, Frighetto L, Loewen P, Sunderji R, Teal P, **Fagan SC**, Marra CA: Cost-Utility analysis of tPA therapy for acute ischemic stroke. A Canadian healthcare perspective. *Pharmacoeconomics* 2001;19(9):927-36.
56. Lyden P, Lu M, Kwiatkowski T, Frankel M, Levine S, Broderick J, Brott T and **the NINDS rt-PA Stroke Study Group**: Thrombolysis in patients with transient neurologic deficits. *Neurology* 2001;57:2125-2128
57. Beard KL, **Fagan SC**: Measuring and improving the quality of care of stroke victims. *Georgia Pharmacist Quarterly* 2002; 79:2-7
58. Kiebert G, Sorensen SV, Revicki D, **Fagan SC**, Doyle JJ, Cohen J, Fivenson D: Atopic Dermatitis Is Associated With a Decrement in Health-related Quality of Life. *Int J Dermatol* 2002;41(3):151-158
59. **Fagan SC**, Lee LA, Hess DC: Role of angiotensin-converting-enzyme inhibitors in stroke prevention. *Am J Health-Syst Pharm* 2003; 60:788-793

60. Ravina BM, **Fagan SC**, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR: Neuroprotective agents for clinical trials in Parkinson's Disease: A systematic assessment. *Neurology* 2003; 60: 1234
61. Chisholm MA, DiPiro JT, **Fagan SC**: An innovative introductory pharmacy practice experience model. *Am J Pharm Edu* (online) 2003; 67(1): article 22
62. **Fagan SC**, Nagaraja TN, Fenstermacher JD, Zheng J, Johnson M, Knight RA: Hemorrhagic transformation is related to the duration of occlusion and treatment with tissue plasminogen activator in a non-embolic stroke model. *Neurol Res* 2003; 25: 377-382
63. Carswell JL, Beard KA, Chevrette MM, Pardue CN, Hess DC, **Fagan SC**. Tracking trends in secondary stroke prevention strategies . *Ann Pharmacother* 2004; 38:215-9.
64. **Fagan SC**. Stroke prevention in the elderly. *Consult Pharm* 2003;18(Suppl A): 10-13
65. **Fagan SC**, Simonson S. A Clinical Consult: Antiplatelet therapy in the management of atherothrombosis in the elderly. *Clinical Consult* 2003;18 (Suppl 1);1-1-1-11
66. Bradberry JC, **Fagan SC**, Gray D, Moon Y: Ischemic Stroke: New perspectives on secondary stroke prevention. *J Am Pharm Assoc* 2004; 44 (suppl 1):S46-S57
67. Hilali HM, Simpkins AN, Hill WD, Waller JL, Knight RA, **Fagan SC**: Single slice method for quantification of hemorrhagic transformation using Direct ELISA. *Neurol Res* 2004; 26:93-98
68. **Fagan SC**, Edwards DJ, Borlongan C, Xu L, Arora A, Feuerstein G, Hess DC. Optimal delivery of minocycline to the brain. Implication for human studies of acute neuroprotection. *Exp Neurol* 2004;186:248-251
69. Hill WD, Hess DC, Martin-Studdard A, Carothers JJ, Zheng J, Hale D, Maeda M, **Fagan SC**, Carroll JE, Conway SJ: SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: Association with bone marrow cell homing to injury. *J Neuropathol Exp Neurol* 2004 ;63:84-96
70. Xu L, **Fagan SC**, Waller JL, Edwards D, Borlongan CV, Zheng J, Hill WD, Feuerstein G, Hess DC. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. *BMC Neurology* 2004, 4:7 (26 Apr 2004)
71. Hanley D, Gorelick PB, Elliott WJ, Saver JL, Kidwell CS, **Fagan SC**, Wilson A, Lennihan L, Schwer WA, Rubenstein LZ, Crowell RM. Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: A

guideline for primary care physicians from the National Stroke Association Work Group on Recurrent Stroke Prevention. *J Stroke Cerebrovasc Dis* 2004;13(5):196-207

72. **Fagan SC**, Hess DC, Pollock DM, Hohnadel EJ, Ergul A. Targets for vascular protection after ischemic stroke. *Stroke* 2004; 35:35:2220-2225

73. **Fagan SC**, Hess DC, Machado LS, Hohnadel EJ, Pollock DM, Ergul A. Tactics for vascular protection after acute ischemic stroke. *Pharmacotherapy* 2005;25(3): 387-395

74. Knight RA, Nagesh V, Nagaraja TN, Ewing JR, Nagesh V, Whitton PA, Bershad E, **Fagan SC**, Fenstermacher JD. Acute blood-brain barrier opening in experimentally induced focal cerebral ischemia is preferentially identified by quantitative magnetization transfer imaging. *Magn Reson Med* 2005;54(4):822-832

75. Knight RA, Nagaraja TN, Ewing JR, Nagesh V, Whitton PA, Bershad E, **Fagan SC**, Fenstermacher JD. Quantitation and localization of blood-to-brain influx by magnetic resonance imaging and quantitative autoradiography in a model of transient focal ischemia. *Magn Reson Med* 2005;54(4):813-821

76. Sachidanandam K, **Fagan SC**, Ergul A. Oxidative stress and cardiovascular disease: antioxidants and unresolved issues. *Cardiovasc Drug Reviews* 2005; 23(2) : 115-132

77. Harris AK, Ergul A, Kozak A, Machado LS, Johnson MH, **Fagan SC**: Effect of neutrophil depletion on gelatinase expression, edema formation and hemorrhagic transformation after focal ischemic stroke. *BMC Neuroscience*, 2005; 6:49

78. Harris AK, Hutchinson JR, Sachidanandam K, Johnson MH, Dorrance AM, Stepp DW, **Fagan SC**, Ergul A. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis. Role of endothelin-1. *Diabetes* 2005;54:2638-2644

79. Libman, R, Kwiatkowski T, Lyden P, Grotta JC, Tilley BC, **Fagan, SC**, Levine, SR, Broderick, J, Lin, Y, Lewandowski C, Frankel, M. Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long - term outcome. *J Stroke Cerebrovasc Dis*, 2005; 2:50 -54.

80. Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, **Fagan S**, Cudkowicz: Neuroprotective agents for clinical trials in ALS: A systematic assessment. *Neurology*. 2006;67(1):20-7.

81. **Fagan SC**, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, Ergul A, Hess DC: Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. *J Hypertens* 2006;24:535-539

82. Elewa HF, Hilali H, Hess DC, Machado LS, **Fagan SC**: Minocycline for short-term

neuroprotection. *Pharmacotherapy* 2006; 26(4):515-521

83. Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR, NINDS tPA Stroke Study Group. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. *Stroke* 2006; 37(10):2508-2513

84. The NINDS NET-PD Investigators. A randomized, double-blinded, futility trial of creatine and minocycline in early Parkinson's Disease. *Neurology* 2006;66:664-671

85. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, **Fagan SC**: Delayed minocycline inhibits ischemia-activated MMP 2 and 9 after experimental stroke. *BMC Neuroscience* 2006;7:56

86. **Fagan SC**, Touchette D, Smith JA, Sowinski KM, Dolovich L, Olson KL, Cheang KI, Kolesar JM, Crismon ML. The state of science and research in clinical pharmacy. *Pharmacotherapy* 2006;26:1027-1040

87. The NINDS NET-PD Investigators. A Randomized Clinical Trial of Coenzyme Q₁₀ and GPI-1485 in Early Parkinson's Disease. *Neurology* 2007;68 20-28

88. Elewa HF, Kozak A, Johnson MH, Ergul A, **Fagan SC**: Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection. *J Hypertens* 2007; 25: 855-859

89. Ergul A, Elgebaly MM, Middlemore ML, Li W, Switzer JA, Hall C, Kozak A, **Fagan SC**. Increased Hemorrhagic Transformation And Altered Infarct Size And Localization After Experimental Stroke In A Rat Model of Type 2 Diabetes. *BMC Neurology* 2007: 7:33

90. **Fagan SC**, Elewa HF, Rychly DJ. Secondary Stroke Prevention with Statin Therapy. Evidence Catches up to Practice. *J Pharmacy Practice* 2007; 20:2:117-122

91. Kozak W, Kozak A, Elewa HF, Johnson MH, **Fagan SC**: Vascular protection with candesartan after experimental acute stroke in hypertensive rats: A dose-response study. *J Pharmacol Exp Ther* 2008; 326(3):773-82

92. **Fagan SC**. Urgent need for secondary stroke prevention after TIA. *Consultant Pharmacist* 2008; 23(2): 131-140

93. Bushnell C, Zimmer L, Schwamm L, Goldstein LB, Clapp-Channing N, Harding T, Drew L, Xhao X, Peterson E. The Adherence evaluation after ischemic stroke longitudinal (AVAIL) registry: design, rationale, and baseline patient characteristics. *Am Heart J* 2009; 157:428-435

94. Kozak A, El-Remessy AB, Ergul A, Machado LS, Elewa HF, Johnson MH, Abdelsaid M, Wiley DA, **Fagan SC**. Candesartan augments ischemia-induced proangiogenic state and results in sustained functional improvement after stroke. *Stroke* 2009; 40:1870
95. Ergul A, Elgebaly M, Li W, Bruno A, **Fagan SC**: Hyperglycemia, diabetes and stroke: Focus on the cerebrovasculature. *Vascular Pharmacol* 2009; 51;44-49
96. Elewa HF, Kozak A, Frye RF, Johnson MH, Ergul A, **Fagan SC**: Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. *J Pharmacol Exp Ther* 2009; 330(2):532-540
97. Machado LS, Sazanova I, Kozak A, Wiley DC, El-Remessy AB, Ergul A, Hess DC, **Fagan SC**. Minocycline and tissue plasminogen activator for stroke: Assessment of Interaction potential. *Stroke* 2009; 40: 3028-3033
98. Li W, Kelly AI, El-Remessy A, Schreihof DA, Kozak A, Dorrance AM, **Fagan SC**, Ergul A. Effects of type 2 diabetes on vascular density, integrity and function of the cerebrovasculature: relevance to focal cerebral ischemia. *Diabetes* 2010;59(1):228-235
99. Elewa HF, El-Remessy AB, Somanath PR, **Fagan SC**: Diverse Effects of Statins on Angiogenesis Open New Therapeutic Avenues. *Pharmacotherapy* 2010;30(2):169-176
100. Hess DC, **Fagan SC**. Repurposing an old drug to improve the safety and use of tissue plasminogen activator for acute ischemic stroke: minocycline. *Rev Neurol Dis* 2010; 7(suppl 1): S7-S13
101. **Fagan SC**. Drug repurposing for drug development in stroke. *Rev Neurol Dis* 2010;7(suppl 1):S3-S6
102. **Fagan SC**. Old drugs, new tricks: Update on stroke therapeutics. *Rev Neurol Dis* 2010;7(suppl 1):S1-S2
103. Hess DC, **Fagan SC**. Repurposing an old drug to improve the safety and use of tissue plasminogen activator for acute ischemic stroke: minocycline. *Pharmacotherapy* 2010 ;30:55S-61S
104. **Fagan SC**. Drug repurposing for drug development in stroke. *Pharmacotherapy* 2010; 30:51S-54S
105. **Fagan SC**. Old drugs, new tricks: Update on stroke therapeutics. *Pharmacotherapy* 2010; 30: 49S-50S
106. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W; ECASS,

ATLANTIS, NINDS and EPITHET rt-PA Study Group, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. *Lancet*. 2010 May 15;375:1695-703

107. **Fagan SC**, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark W, Hall C, Switzer JA, Ergul A, Hess DC. Minocycline to Improve Neurologic Outcome in Stroke (MINOS): A dose finding study. *Stroke* 2010; 41:2283-2287

108. Elgebaly MM, Prakash R, Li W, Ogbi S, Johnson MH, Mezzetti EM, **Fagan SC**, Ergul A. Vascular protection in diabetic stroke: Role of matrix metalloprotease-dependent vascular remodeling. *J Cerebral Blood Flow Metab* 2010;120: 1-11

109. **Fagan SC**. Commentary (Invited): Measuring disease-free life after thrombolysis. *Nat Rev Neurol* 2010; 6:361-362

110. Li W, Kelly-Cobbs AI, Mezzetti EM, **Fagan SC**, Ergul A. Endothelin-1-mediated cerebrovascular remodeling is not associated with increased ischemic brain injury in diabetes. *Can J Physiol Pharmacol* 2010;Aug; 88(8):788-795

111. Bushnell CD, Zimmer LO, Pan W, Olson DM, Zhao X, Meteleva T, Schwamm L, Ovbiogele B, Williams L, LaBresh KA, Peterson ED, for the Adherence Evaluation after Ischemic Stroke – Longitudinal Investigators. Persistence with stroke prevention medications 3 months after hospitalization. *Arch Neurol* 2010;67:1456-1463

112. Willis, LM, Somanath PR, El-Remessy AB, Deremer DL, **Fagan SC**. Angiotensin receptor antagonists and angiogenesis: Clinical and Experimental Evidence. *Clinical Science* 2011; 120(8): 307-319

113. Furie KL, Kasner SE, Adams RJ, Albers G, Bush RL, **Fagan SC**, Halperin J, Johnson SC, Katzan I, Kernan WN, Mitchell P, Obviagele B, Palesch Y, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan T, Wentworth D. Guidelines for the prevention of stroke in patients with ischemic stroke or transient ischemic attack. *Stroke* 2011;42(1):227-76

114. Guan W, Kozak A, El-Remessy AB, Johnson MH, **Fagan SC**. Acute treatment with candesartan reduces early injury after permanent middle cerebral artery occlusion. *Translational Stroke Research* 2011; 2(2): 179-185

115. Switzer JA, Hess DC, Waller JL, Ergul A, Portik-Dobos V, Machado LS, **Fagan SC**. MMP 9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. *Stroke* 2011; 42: 2633-2635

116. **Fagan SC**, Cronin LE, Hess DC. Minocycline development for acute ischemic stroke (Invited). *Translational Stroke Research* 2011;2(2):202
117. Guan W, Kozak A, **Fagan SC**. Drug repurposing for vascular protection after acute ischemic stroke. *Acta Neurochir Supp* 2011; 49:295-298
118. Alhusban A, **Fagan, SC**. Secondary Stroke Prevention in the Elderly (invited). *Am J Ger Pharmacother* 2011; 9(3):143-152
119. Bushnell CD, Olson DWM, Zhao X, Pan W, Zimmer LO, Alberts MJ, **Fagan SC**, Fonarow GC, Frankel M, Johnston SC, Kidwell C, LaBresh KA, Ovbiagele B, Schwamm L and Peterson ED for the AVAIL investigators. Secondary Preventive Medication Persistence and Adherence One-Year After stroke: Results from AVAIL. *Neurology* 2011; 77:1182-1190
120. Elgebaly MM, Ogbi S, Li W, Mezzetti E, Prakash R, Johnson MH, Bruno A, **Fagan SC**, Ergul A. Neurovascular outcomes in acute hyperglycemia and diabetes: A comparative analysis in experimental stroke. *Translational Stroke Research* 2011; 2(3):391-398
121. Guan W, Somanath PR, Kozak A, Goc A, El-Remessy AB, Ergul A, Johnson MH, Alhusban A, Soliman S, **Fagan SC**. Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after stroke. *Plos One* 2011; 6(9): e24551
122. Wrotek S, Kozak W, Hess DC, **Fagan SC**. Fever following stroke: Conflicting evidence regarding treatment. *Pharmacotherapy* 2011;31(11):1085-1091
123. Ergul A, Kelly-Cobbs A, Abdalla M, **Fagan SC**. Cerebrovascular complications of diabetes (invited). *Endocrine, Metabolic and Immune Disorders-Drug Targets* (EMID-DT) 2012; 12:148-158
124. Prakash R, Somanath PR, El-Remessy AB, Kelly-Cobbs A, Stern JE, Dore-Duffy P, Johnson M, **Fagan SC**, Ergul A. Enhanced cerebral but not peripheral angiogenesis in the Goto-Kakizaki model of type 2 diabetes involves VEGF and peroxynitrite signaling. *Diabetes* 2012; 61:1533-1542
125. Switzer JA, Sikora A, Hess DC, Waller JL, Ergul A, **Fagan SC**. Minocycline prevents IL-6 increase after acute ischemic stroke. *Translational Stroke Research*, 2012; Sep 1;3(3):363-368
126. Ishrat T, Soliman S, Guan W, Saler M, **Fagan SC**. Vascular protection to increase the safety of tissue plasminogen activator for stroke. *Curr Pharm Design* 2012; 18(25):3677-84

127. Ergul A, Alhusban A, **Fagan SC**. Angiogenesis: A Harmonized Target for Recovery after Stroke (Invited). *Stroke* 2012; 43:2270-2274
128. Boudreau D, Guzauskas G, Villa K, **Fagan SC**, Veenstra D. Cost effectiveness of tissue plasminogen activator 3-4.5 hours after onset of acute ischemic stroke. *Ann Emerg Med* 2012 May 24. Epub ahead of print, PMID: 22633340
129. Switzer JA, Rocker JL, Mohorn P, Waller JL, Hughes D, Bruno A, Nichols FT, Hess DC, Natarajan K, **Fagan SC**. Incomplete reversal of anticoagulation following intracranial hemorrhage using three-factor prothrombin complex concentrate. *Stroke* 2012;43(9):2500-2
130. Hoda MN, Siddiqui S, Herberg S, Periyasamy-Thandavan S, Bhatia K, Johnson MH, Hafez SS, Hill WD, Ergul A, **Fagan SC**, Hess DC. Remote ischemic preconditioning is effective alone and in combination with intravenous tissue plasminogen activator in murine model of embolic stroke. *Stroke* 2012; 43(10):2794-9
131. Matragoon S, Al-Gayyar MMH, Mysona BA, Abdelsaid MA, Pillai BA, Neet KE, **Fagan SC**, El-Remessy AB. Electroporation-mediated gene delivery of cleavage-resistant pro-Nerve Growth Factor causes retinal neuro- and vascular degeneration. *Molecular Vision* 2012;18:2993-3003
132. Alhusban A, Kozak A, Ergul A, **Fagan SC**. AT1 receptor antagonism modulates the angiogenic response of brain endothelial cells to angiotensin II: BDNF a novel mediator. *J Pharmacol Exp Ther* 2013; 344(2):348-359
133. **Fagan SC**, Lapchak PA, Liebeskind DS, Ishrat T, Ergul A. Recommendations for preclinical research in hemorrhagic transformation. *Transl Stroke Res* 2013;4:322-327
134. Kelly-Cobbs AI, Prakash R, Li W, Pillai B, Coucha M, Johnson MH, Oghi S, **Fagan SC**, Ergul A. Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes. *Am J Physiol Heart and Circ Physiol*. 2013; 304(6):H806-815
135. Baker WL, Marrs JC, David LE, Nutescu EA, Rowe AS, Ryan MA, Splinter MY, Vardeny O, **Fagan SC**. Key articles and guidelines in the primary prevention of ischemic stroke. *Pharmacotherapy*, epub ahead of print, February, 2013
136. Baker WL, Marrs JC, David LE, Nutescu EA, Rowe AS, Ryan MA, Splinter MY, Vardeny O, **Fagan SC**. Key articles and guidelines in the acute treatment and secondary prevention of ischemic stroke. *Pharmacotherapy*, epub ahead of print, February, 2013
137. Prakash R, Johnson M, **Fagan SC**, Ergul A. Cerebral neovascularization and remodeling patterns are different in obese and lean models of Type 2 diabetes. *PLoS ONE* 2013;8(2):e56264, February 18

138. Liao TV, Forehand CC, Hess DC, **Fagan SC**. Minocycline repurposing in critical illness: Focus on stroke. *Curr Top Med Chem* 2013; 13(18)
139. Prakash R, Li W, Qu Z, Johnson MH, **Fagan SC**, Ergul A. Vascularization pattern after ischemic stroke is different in control versus diabetic rats: Relevance to stroke recovery. *Stroke* 2013; 44(10):2875-2882
140. Coucha M, Li W, Johnson MA, **Fagan SC**, Ergul A. Protein nitration impairs myogenic tone of rat middle cerebral arteries in both ischemic and nonischemic hemispheres after ischemic stroke. *AJP, Heart and Circ Phys* 2013 ePub ahead of print, October 4
141. Li W, Qu Z, Ma H, Prakash R, Chung C, Hoda N, **Fagan SC**, Ergul A. Comparative analysis of the neurovascular injury and functional outcomes in experimental stroke models in diabetic Goto-Kakizaki rats. *Brain Res* 2013; Oct 18. doi:pii: S0006-8993(13)01412-1
142. Ishrat T, Pillai B, Ergul A, Hafez S, **Fagan SC**. Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke. *Neurochem Res* 2013; November 6, epub ahead of print
143. Fouda A, Kozak A, Alhusban A, Switzer JA, **Fagan SC**. Antiinflammatory IL-10 is upregulated in both hemispheres after experimental ischemic stroke: Hypertension blunts the response. *Exp Translational Stroke Med* 2013, 5:12 DOI:10.1186/2040-7378-5-12. Nov 13
144. Hoda MN, Bhatia K, Hafez SS, Johnson MH, Siddiqui S, Ergul A, Zaidi SK, **Fagan SC**, Hess DC. Remote ischemic preconditioning is effective after embolic stroke in ovariectomized female mice. *Translational Stroke Research* 2014, epub Jan.4
145. Ergul A, Abdelsaid M, Fouda A, **Fagan SC**. Cerebral neovascularization in diabetes: Implications for stroke recovery and beyond. Invited Review, *J Cerebr Blood Flow Metab*; 2014; 34(4):553-563; doi:10.1038/jcbfm.2014.18
146. Hafez S, Coucha M, Bruno A, **Fagan SC**, Ergul A. Hyperglycemia, acute ischemic stroke and thrombolytic therapy. *Translational Stroke Research* 2014; March 13; DOI: 10.1007/s12975-014-0336-z
147. Soliman SA, Ishrat T, Pillai A, Somanath PR, Ergul A, El-Remessy AB, **Fagan SC**. Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after glucose deprivation: Role of VEGF-A and VEGF-B. *J Pharmacol Exp Ther* 2014; 349 (3):444-457; DOI: 10:1124/jpet.113.212613
148. Ishrat T, El-Remessy AB, Mohamed IN, Pillai B, Soliman S, Ergul A, **Fagan SC**. Thioredoxin interacting protein: A novel target for neuroprotection in experimental

thromboembolic stroke in mice. *Mol Neurobiol* 2015;51(2):766-778; Erratum published, 2015;51(2):779-780

149. Coucha M, Li W, Johnson MH, **Fagan SC**, Ergul A. Reply to “Letter to the editor: Targeting cerebrovascular myogenic dysfunction in stroke”. *Am J Physiol Heart Circ Physiol*. 2014; 306(10): H1483

150. Alhusban A, Al-Azayzih A, Goc A, **Fagan SC**, Somanath PR. Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts *in vivo* through modulation of tumor angiogenesis. *J Pharmacol Exp Ther* 2014; 350(3): 635-645. DOI:114.216382; PMID:24990940

151. Ishrat T, Kozak A, Alhusban A, Pillai B, El-Remessy AE, Johnson MH, Ergul A, **Fagan SC**. Role of matrix metalloproteinase activity in the neurovascular protective effects of angiotensin antagonism. *Stroke Research and Treatment* 2014; doi:10.1155/2014/560491; epub July 24

152. Ishrat T, Pillai B, Soliman S, Fouda AY, Kozak A, Johnson MH, Ergul A, **Fagan SC**. Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats. *Mol Neurobiol* 2015;51(3):1542-1553

153. Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, **Fagan SC**, Veenstra DL. Cost-effectiveness of recombinant tissue plasminogen activator within 3 hours of acute ischemic stroke: Current Evidence. *Stroke* 2014; 45(10):3032-3039; ePub ahead of print, September 4, 2014; DOI: 10.1161. STROKEAHA.114.005852

154. Mohamed IN, Ishrat T, **Fagan SC**, El-Remessy AB. Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit. Invited Review. *Antioxidants and Redox Signaling* 2015;22(13):1188-1206; ePub October 2, 2014

155. Alhusban A*, Fouda AY*, Pillai B, Ishrat T, Soliman S, **Fagan SC**. C21 is proangiogenic in the brain and results in sustained recovery after ischemic stroke. *J Hypertension* 2015; 33(1):170-180; epub October 8, 2014

156. Khan M, Hoda MN, Vaibhav K, Giri S, Waller J, Ergul A, Dhandapani K, **Fagan SC**, Hess DC. Remote ischemic postconditioning: Harnessing endogenous protection in a murine model of vascular cognitive impairment. *Translational Stroke Research*, 2015;6(1):69-77

157. Hoda MD, **Fagan SC**, Khan MB, Vaibhav K, Chaudhary A, Wang P, Dhandapani KM, Waller JL, Hess DC. A 2x2 factorial design of minocycline and remote ischemic preconditioning prior to thrombolysis in acute ischemic stroke. *Experimental and*

Translational Stroke Medicine 2014; 6:10; doi: 10.1186/2014-7378-6-10

158. Shanab AY, El-Azab MF, Sabbineni H, Soliman S, Matragoon S, **Fagan SC**, El-Remessy AB. Candesartan preserves retinal vasculature in ischemic retinopathy: Role of inducible nitric oxide synthase (iNOS) and Hemeoxygenase-1 (HO-1). *Angiogenesis* 2015;18(2):137-150

159. Abdelsaid M, Prakash R, Li W, Coucha W, Hafez S, Johnson MH, **Fagan SC**, Ergul A. Metformin treatment in post-stroke period prevents nitrative stress and restores angiogenic signaling in the brain in diabetes. *Diabetes* 2015; 64(5); 1804-1817; ePub Dec. 18, 2014

160. Coucha M, Li W, Hafez S, Abdelsaid M, Johnson MH, **Fagan SC**, Ergul A. SOD1 overexpression prevents acute hyperglycemia-induced cerebral myogenic dysfunction: Relevance to contralateral hemisphere and stroke outcomes. *Am J Physiol Heart Circ Physiol* 2015; 308(5):H456-466

161. Hafez S, Hoda MN, Guo X, **Fagan SC**, Ergul E. Comparative analysis of different methods of ischemia/ reperfusion in hyperglycemic stroke outcomes: Interaction with tPA. *Translational Stroke Research* 2015; 6(3): 171-180; epub Feb. 17

162. Ahmed H, May, DW, **Fagan SC**, Segar L. Vascular protection with Dipeptidyl peptidase-IV inhibitors in diabetes: Experimental and Clinical Therapeutics. *Pharmacotherapy* 2015;35(3):277-97

163. Ergul A, Valenzuela JP, Fouda A, **Fagan SC**. Cellular connections, microenvironment and brain angiogenesis in diabetes: Lost communication signals in the post-stroke period. (Invited Review). *Brain Research* 2015; 1623:81-96

164. Artham S, Fouda AY, El-Remessy AB, **Fagan SC**. Vascular protective effects of angiotensin receptor blockers: Beyond blood pressure. *Receptors and Clinical Investigation* 2015; 2:e774. Doi:10.14800/rci.774

165. Soliman SA, Ishrat T, Fouda AY, Patel A, Pillai B, **Fagan SC**. Sequential therapy with minocycline and candesartan improves long term recovery after experimental stroke. *Translational Stroke Research* 2015;6(4): 309-322

166. Abdalla M, Sabbineni H, Prakash R, Ergul A, **Fagan SC**, Somanath PR. Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGF β -induced pulmonary fibrosis. *Br J Pharmacol* 2015;172(16):4173-4188

167. Fouda AY, Artham S, El-Remessy AB, **Fagan SC**. Renin angiotensin system as a potential therapeutic target in stroke and retinopathy: Experimental and clinical evidence. *Clin Sci* 2016; 130(4): 221-238

168. Alhusban A, Fouda AY, Ishrat T, Pillai B, Eldahshan W, Waller JL, Ergul A , **Fagan**

SC. Brain derived neurotrophic factor knockdown blocks the angiogenic and protective effects of angiotensin modulation after experimental stroke. *Molecular Neurobiol*; ePub, Jan 12, 2016

169. Hafez S, Abdelsaid M, El-Shafey S, Johnson MH, **Fagan SC**, Ergul A. Matrix metalloprotease 3 exacerbates hemorrhagic transformation and worsens functional outcomes in hyperglycemic stroke. *Stroke* 2016;47:00-00.
DOI:10.1161/STROKEAHA.115.011258

170. Ergul A, Hafez S, Fouda AY, **Fagan SC**. Impact of comorbidities on acute injury and recovery in preclinical stroke research: Focus on hypertension and diabetes. (Invited Review). *Translational Stroke Research* ePub: March 30, 2016.

171. Alhusban A, Kozak A, Eldahshan W, Ergul A, **Fagan SC**. Artery reopening is required for the neurorestorative effects of angiotensin modulation after experimental stroke. *Experimental and Translational Stroke Medicine* 2016; ePub, April 27
DOI:10.1186/s13231-016-0018

172. Alhusban A, Fouda AY, **Fagan SC**. ARBs improve stroke outcome through an AT2 dependent, BDNF induced proangiogenic and prorecovery response. *Neural Regeneration Research (Invited)* 2016;11(6):912-913

173. Coucha M, Abdelsaid M, Li W, Johnson MH, Orfi L, El-Remessy AB, **Fagan SC**, Ergul A. Nox4 contributes to the hypoxia-mediated regulation of actin cytoskeleton in cerebrovascular smooth muscle. *Life Sci* 2016; 163:46-54

174. Fouda AY, Pillai B, Dhandapandi KM, Ergul A, **Fagan SC**. Role of interleukin-10 in the neuroprotective effect of the angiotensin type II receptor agonist, compound 21, after ischemia/ reperfusion injury. *Eur J Pharmacol* 2017; 799:128-134

175. Li W, Ward R, Valenzuela JP, Dong G, **Fagan SC**, Ergul A. Diabetes worsens functional outcomes in young female rats: Comparison of stroke models, tissue plasminogen activator effects and sexes. *Translational Stroke Research* 2017; ePub Mar 1

176. Alhusban A, Kozak A, Pillai B, Ahmed H, Sayed MA, Johnson MH, Ishrat T, Ergul A, **Fagan SC**. Mechanisms of acute neurovascular protection with AT1 blockade after stroke: effect of premorbid hypertension. *PloS One* 2017;12(6):e0178867

177. Fouda AY, Newsome AS, Spellicy S, Waller JL, Zhi W, Hess DC, Ergul A, Edwards DJ, **Fagan SC**, Switzer JA. Minocycline in acute cerebral hemorrhage: An early phase randomized trial. *Stroke* 2017; 48(10):2885-2887

178. Hafez S, Abdelsaid M, **Fagan SC**, Ergul A. Peroxynitrite induced tyrosine nitration

contributes to Matrix Metalloprotease-3 activation: Relevance to hyperglycemic ischemic brain injury and tissue plasminogen activator. *Neurochem Res* 2017; 43(2): 259-266

179. Ahmed HA, Ishrat T, Pillai B, Patel A, Bunting K, Vazdarjanova A, Waller JL, Arbab AS, Ergul A, **Fagan SC**. Role of angiotensin system modulation on progression of vascular cognitive impairment and MRI changes in aged hypertensive animals – A randomized, double-blind, preclinical study. *Behav Brain Res* 2018; Jul 2;346:29-40.

180. Ishrat T, Fouda FY, Pillai B, Eldahshan W, Ahmed H, Waller JL, Ergul A, **Fagan SC**. Dose-response, therapeutic time-window, and tPA-combinatorial efficacy of compound 21: a randomized, blinded, preclinical trial in a rat model of thromboembolic stroke. *J Cerebr Blood Flow Metab* 2018;39(8):1635-1647

181. Jackson L, Eldahshan W, **Fagan SC**, Ergul A. Within the brain: The Renin Angiotensin System (Invited Review). *Int J Molec Sci* 2018;19(3)

182. Miller S, Wood EA, Fulford M, **Fagan S**, Wallach P. Medicine Pharmacy Interprofessional Exercise Pilot: Lessons Learned. *MedEdPublish* March 22, 2018

183. Ishrat T*, Soliman S*, Eldahshan W, Pillai B, Ergul A, **Fagan SC**. Silencing VEGF-B diminishes the neuroprotective effect of candesartan treatment after experimental focal cerebral ischemia. * = equal contribution. *Neurochem Res* 2018; 43(10):1869-1878

184. Ahmed HA, Ishrat T, Pillai B, Fouda AY, Sayed MA, Waller JL, Ergul A, **Fagan SC**. RAS modulation prevents progressive cognitive impairment in hypertensive animals after experimental stroke. *J Neuroinflam* 2018 Aug 13;15(1):229

185. Ward R, Valenzuela JP, Li W, Dong G, **Fagan SC**, Ergul A. Post stroke cognitive impairment and hippocampal neurovascular remodeling: Impact of diabetes and sex. *AJP – Heart Circ Physiol* 2018; 315: H1402-H1413

186. Ahmed HA, Ishrat T, Pillai B, Bunting K, Vazdarjanova A, Waller JL, Ergul A, **Fagan SC**. Angiotensin receptor (AT2R) agonist C21 prevents cognitive impairment after distal middle cerebral artery occlusion in aged rats. *Behav Brain Res* 2019; 359:560-569

187. Li W, Valenzuela JP, Ward R, Abdelbary M, Dong G, **Fagan SC**, Ergul A. Post-stroke neovascularization and functional outcomes differ in diabetes depending on severity of injury and sex. *Exp Neurol* 2019;311:106-114

188. Ward R, Abdul Y, Dong G, Jamil S, Jackson L, **Fagan SC**, Li W, Filosa J. NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive impairment and vasoneuronal remodeling after ischemia. *Pharmacol Res*; 2019;

142:237-250

189. Fouda AY, **Fagan SC**, Ergul A. The brain vasculature and cognition: Renin angiotensin system, endothelin and beyond. (Invited Review). *ATVB* 2019; Mar 1 (epub ahead of print)

190. Eldahshan W, Ishrat T, Pillai B, Sayed M, Alwhaibi A, Fouda A, Ergul A, **Fagan SC**. Angiotensin type 2 receptor stimulation with Compound 21 improves stroke outcome in female rats: Possible role for peroxisome proliferator-activated receptor- λ . *AJP-Heart Circ Physiol*; 2019: 316(5); H1192-H1201

191. Phan SV, Osaie S, Morgan J, Inyang M, **Fagan SC**. Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the United States. *Drugs in R&D*, 2019; 19(2):93-115

192. Eldahshan W, **Fagan SC**, Ergul A. Inflammation in the Neurovascular Unit: Focus on microglia for stroke injury and recovery. *Pharmacol Res* 2019; 147:10439

193. Jackson L, Dong G, Althomali W, Sayed MA, Eldahshan W, Baban B, Johnson MH, Filosa J, **Fagan SC**, Ergul A. Delayed administration of angiotensin II Type 2 receptor agonist Compound 21 prevents the development of post-stroke cognitive impairment in diabetes through the modulation of microglia polarization. *Translational Stroke Research* 2020; Doi:10.1007/s12975-019-00752-5

194. Jackson L, Dumlani S, Johnson MH, **Fagan SC**, Ergul A. Microglial knockdown reduces inflammation and preserves cognitive function in diabetic animals after experimental stroke. *J Neuroinflammation* 2020; April 28:17(1):137

195. Abdul Y*, Li W*, Ward R, Abdelsaid M, Hafez S, Dong G, Jamil S, Wolf V, Johnson MH, **Fagan SC** and Ergul A. Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis. Accepted, *Transl. Stroke Res.* 2020

Abstracts

1. Gengo, F.M., **Fagan, S.C.*** and McHugh, W.B. Propranolol concentrations in migraine prophylaxis. 5th Annual Meeting of the American College of Clinical Pharmacy, San Diego, CA., 1984

2. Gengo, F.M., Castellani, D.A., **Fagan, S.C.*** Cerebrospinal fluid prostanoid

concentrations in ischemic stroke. 37th Annual Meeting of the American Academy of Neurology, Dallas, TX, 1985

3. Gengo, F.M.*, Huntoon, L., **Fagan, S.C.** Simultaneous pharmacodynamics of multiple actions of metoprolol. 86th Annual of the American Society of Clinical Pharmacology and Therapeutics, San Antonio, TX, 1985

4. **Fagan, S.C.***, Gengo, F.M., Bernhard, H., Krol, G. Evaluation of oral and sublingual nimodipine in hepatic cirrhosis: disposition and drug effect. 87th Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, Washington, D.C., 1986

5. **Fagan, S.C.***, Levine, S.R., Kinkel, W.R., Gengo, F.M. Effect of nimodipine on blood pressure in acute stroke. 88th Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, Orlando, Fla., March, 1987

6. **Fagan, S.C.*** and Gengo, F.M. Time course of changes in CSF Thromboxane B2 concentrations in experimental cerebral ischemia. 39th Annual Meeting of the American Academy of Neurology, New York, New York, April 5-11, 1987

7. Levine SR *, **Fagan SC**, Floberg J, Selwa JF, Vogel CM. Moyamoya, oral contraceptives, and cigarette use. 113th Annual Meeting of the American Neurological Association, Philadelphia, PA., October, 1988

8. Levine SR*, Welch KMA, Gdowski JW, Chopp M, Brown GG, **Fagan SC**, Deitrich K, Pajean AK, Helpert JA: The significance of acid-base status in ischemic human stroke. 14th International Joint Conference on Stroke and Cerebral Circulation, San Antonio, TX., Feb., 1989

9. **Fagan SC***, Levine SR, Steigerwalt SP, Robertson WM, Welch KMA: Intracerebral "steal" and antihypertensive therapy in the elderly. 90th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Nashville, TN., March, 1989

10. **Fagan SC***, Levine SR, Ewing JR, Steigerwalt SP, Welch KMA: Carotid artery disease and cerebral blood flow response to antihypertensive therapy. 41st Annual Meeting of the American Academy of Neurology, Chicago, Il., April, 1989

11. **Fagan SC***, Levine SR, Ewing JR, Steigerwalt, SP, Welch KMA: Cerebral blood flow changes following antihypertensive therapy in the patients at risk of stroke. XVI International Symposium on Cerebral Blood Flow and Metabolism, Bologna, Italy, May, 1989

12. Branch CA*, Ewing JR, **Fagan SC**, Butt S, Simkins R, Welch KMA: Toxicity of potential fluorinated indicators for NMR measurements of CBF. XVI International

Symposium on Cerebral Blood Flow and Metabolism, Bologna, Italy, May, 1989

13. Ewing JR*, Branch CA, **Fagan SC**, Helpert JA, Welch KMA: Multi-compartmental measurement of CBF using FC-23 and 19-F NMR detection. XVI International Symposium on Cerebral Blood Flow and Metabolism, Bologna, Italy, May, 1989

14. Levine SR*, Welch KMA, Gdowski JW, Chopp M, **Fagan SC**, Brown GG, Deitrich K, Pajean AK, Helpert JA: Brain pH correlates with energy metabolism and clinical outcome in early human ischemic stroke. 19th Annual Michigan Cardiovascular Research Forum, Detroit, MI, Sept, 1989

15. **Fagan SC***, Levine SR, Ewing JR, Welch KMA: Racial differences in cerebrovascular response to antihypertensive therapy. 91st Annual Meeting of The American Society for Clinical Pharmacology and Therapeutics, San Francisco, CA, March, 1990

16. **Fagan SC***, Lewis KS, Silvas VA, Steigerwalt SP, Ramadan NM: Effect of nifedipine on cerebral blood flow using transcranial doppler (TCD) ultrasonography. 11th Annual Meeting of the American College of Clinical Pharmacy, San Francisco, CA, August, 1990

17. Ramadan NM*, Lewis KS, Silvas VA, Steigerwalt SP, **Fagan SC**: Effect of nifedipine on cerebral blood flow using transcranial doppler (TCD) ultrasonography. Annual Meeting of the American Neurological Association, Atlanta, GA, March, 1990

18. Levine SR*, Welch KMA, **Fagan SC**, Sawaya KL, Vande Linde AMQ, Chopp M, Pajean AK, Helpert JA : The value of serially monitoring human focal cerebral ischemic acid-base shifts: Novel insights from nimodipine. Submitted to American Heart Association of Michigan Cardiovascular Research Forum, May, 1990

19. Ramadan NM*, Robert S, **Fagan SC**: The effect of nimodipine challenge on MCA velocity in migraineurs and controls. International Symposium on Intracranial Hemodynamics. San Francisco, CA, Feb., 1991

20. Robert S, **Fagan SC***, Bindlish V, Ramadan NM: Cerebral hemodynamics in migraineurs. A preliminary report of the effects of nimodipine. American College of Clinical Pharmacy. 1991 Winter Practice and Research Forum, Ft. Lauderdale, Fla, Feb., 1991

21. **Fagan SC***, Levine SR, Ewing JR, Ramadan NM, Welch KMA: Age and carotid disease are important determinants of iatrogenic cerebral hypoperfusion risk. 17th International Joint Conference on Stroke and Cerebral Circulation, Phoenix, AZ, January, 1992

22. Jahns BE*, Mlynarek M, Zarowitz BJ, Patel R, **Fagan SC**: Labetolol safety and efficacy in acute stroke patients. ACCP 1992 Winter Practice and Research Forum, Phoenix, AZ, Feb., 1992

23. **Fagan SC**, Patel RV*, Ramadan NM, Levine SR: Cerebral blood flow response to ramiprilat, enalaprilat and placebo in hypertensive patients with carotid artery occlusive disease. 1994 Winter Practice and Research Forum of the American College of Clinical Pharmacy, San Diego, CA, Feb., 1994
24. **Fagan SC***, Rahill AA, Balakrishnan G, Ewing JR, Branch CA, Brown GG: Phase I evaluation of trifluoromethane. Ninety-fifth Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, New Orleans, Louisiana, March, 1994
25. Rahill AA*, Brown GG, **Fagan SC**, Ewing J, Branch CA: Neuropsychological contribution to a Phase I investigative new drug study. American Psychological Association - 1994 Annual Meeting, Los Angeles, CA, Aug., 1994
26. **Fagan SC***, Bowes MP, Thomas GR, Zivin JA: Peak blood pressure and hemorrhagic transformation after embolic stroke. 20th International Conference on Stroke and Cerebral Circulation, Charleston, SC, Feb., 1995
27. Chant C, **Fagan SC***, Grover S, Gidal BE, Joseph R: Ticlopidine and aspirin and platelet function in smokers and non-smokers. 1995 Annual Meeting of the American College of Clinical Pharmacy, Washington, D.C., Aug., 1995
28. Smythe M*, **Fagan SC**, Marinac B, Shamoun J, Thomas H: Heparin resistance: Definition and risk factors. 1996 Annual meeting of American Society for Clinical Pharmacology and Therapeutics, March 20-22, 1996, Orlando, FL
29. Mitsias P*, Bennett D, Chase H, **Fagan SC**: Outcomes associated with mannitol use in ischemic cerebral edema. 1996 American Academy of Neurology Annual Meeting, San Francisco, Ca, March, 1996
30. **Fagan SC***, Garcia JH: Reperfusion hemorrhage after middle cerebral artery occlusion in the rat. 1996 American Academy of Neurology Annual Meeting, San Francisco, CA, March, 1996
31. Knight RA*, **Fagan SC**, Barker PB, Welch KMA: Observation of hemorrhagic conversion in ischemic brain tissue following transient middle cerebral artery occlusion in the rat. 1996, Annual Meeting of Magnetic Resonance in Medicine, New York, NY, May, 1996
32. Knight RA*, **Fagan SC**, Barker PB, Welch KMA: MRI assessment of hemorrhagic transformation in stroke. AHA 22nd International Joint Conference on Stroke and Cerebral Circulation., Anaheim, CA, Feb., 1997
33. **Fagan SC***, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Broderick JP, Levine SR, Kwiatkowski T, Frankel M, Walker MD and the NINDS rt-PA Stroke Study

Group: rt-PA reduces length of stay and improves disposition following stroke. AHA 22nd International Joint Conference on Stroke and Cerebral Circulation., Anaheim, CA, Feb., 1997

34. **Fagan SC***, Bowes MP, Lyden PD, Zivin JA: Hypertension and hemorrhagic transformation in experimental stroke: Effect of labetalol. AHA 23rd International Joint Conference on Stroke and Cerebral Circulation, Orlando, FL, Feb., 1998

35. Knight RA*, Ewing JR, **Fagan SC**, Chopp M: Magnetization transfer contrast MRI in hemorrhagic transformation of ischemic stroke. AHA 24th International Joint Conference on Stroke and Cerebral Circulation, Nashville, TN, Feb., 1999

36. **Fagan SC***, Lovell KL, Garcia JH: Time to reperfusion is an important determinant of hemorrhagic transformation in experimental focal ischemia. AHA 24th Annual International Joint Conference on Stroke and Cerebral Circulation, Nashville, TN, Feb., 1999

37. Grotta JC*, Welch KMA, **Fagan SC**, Lu M, Frankel MR, Brott T, Levine SR, Lyden PD for the NINDS tPA Stroke Study Group. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. AHA 26th International Stroke Conference, Fort Lauderdale, FL,, Feb, 2001

38. **Fagan SC***, Knight RA, Kinnaird A. Hemorrhagic transformation: Influence of occlusion duration, infarct size and tissue plasminogen activator in experimental stroke. AHA 26th International Stroke Conference, Fort Lauderdale, FL,, Feb, 2001

39. Robinson VJB*, Pipkin WL, Corley JH, Eubig C, **Fagan SC**, Gossage JR, Reece SJ, Jonah MH, Rawson JV, Abdulla AM: Mini-dose tissue plasminogen activator (tPA) amplifies D-Dimer signal in deep venous thrombosis in swine. ACC Scientific Sessions, July, 2000

40. Jacobs C*, **Fagan SC**: Prevention of hemorrhagic transformation after acute ischemic stroke. 2001 ACCP Spring Practice and Research Forum, Salt Lake City, UT, April, 2001

41. Knight RA*, Ewing JR, Nagaraja TN, Nagesh V, Arniago P, **Fagan SC**, Jiang Q, Fenstermacher JD: Altered BBB permeability in acute stroke studied by Gd-DTPA enhanced T1-weighted imaging and 14C-autoradiography. International Society for Magnetic Resonance in Medicine, Edinburgh, Scotland, April, 2001

42. Ricci JF*, Silverstein MD, **Fagan SC**, Martin BC: Development and validation of prospective cost risk adjustment indices using administrative medical and drug information for stroke patient in Medicaid populations. AHSR, January, 2001

43. **Fagan SC***, Pardue C, Nichols FT, Adams RJ, Pruitt JN, Hess DC: Secondary Stroke Prevention – Stroke Service Experience. First National CDC Prevention Conference on Heart Disease and Stroke, Atlanta, GA, August, 2001

44. **Fagan SC***, Martin BC, Cantrell CR, Hess DC: Secondary Stroke Prevention Gap. First National CDC Prevention Conference on Heart Disease and Stroke, Atlanta, August, 2001
45. Ricci JF*, **Fagan SC**, Martin BC. "Development and independent validation of prospective mortality risk-adjustment models for incident cases of ischemic and hemorrhagic stroke based on automated pharmacy and medical claims data," American Neurological Association 126th Annual Meeting, Chicago, September, 2001
46. Hickenbottom SL*, **Fagan SC**, L'Italien G, Franic DM, Akehurst RL, Brass LM, Tuomari AV, Johnson CA for the POST Outcomes Steering Committee. "International differences in healthcare utilization in the 12-month period following acute ischemic stroke". American Stroke Association, 28th Annual International Stroke Conference, Phoenix, AZ, Feb., 2003
47. Fenstermacher JD*, Knight RA, Nagaraja TN, Nagesh V, Arniago P, Yee J, **Fagan SC**, Randall KA, Ewing JR. "Elevated blood-brain transfer constants of Gd-DTPA and water indicate early barrier opening in MRI studies of hemorrhagic transformation in rats. American Stroke Association, 28th Annual International Stroke Conference, Phoenix, AZ, Feb., 2003
48. Hill WD*, Hess DC, Carroll JE, **Fagan SC**, Martin-Studdard A, Brailer J, Carothers J, Zheng J, Hale D." The bone marrow cell homing signal, SDF-1, is upregulated in the ischemic penumbra following stroke. American Stroke Association, 28th Annual International Stroke Conference, Phoenix, AZ, Feb., 2003
49. **Fagan SC***, Harris AK, Ergul A, Simpkins AN, Hill WD, Hess DC. "Neutrophil depletion reduces hemorrhagic transformation after temporary cerebral ischemia." American Stroke Association, 28th Annual International Stroke Conference, Phoenix, AZ, Feb., 2003
50. Jauch EC*, Lindsell C, Broderick J, Lin Y, Tilley B, **Fagan SC**. "Serum Myelin Basic Protein, Neuron Specific Enolase, S-100b and Thrombomodulin: Potential biochemical markers associated with acute ischemic stroke in the NINDS rt-PA Stroke Trial. American Stroke Association, 29th Annual International Stroke Conference, San Diego, CA, Feb., 2004
51. Miller J, Bartley J, Wimborne HC, Carroll J, Stanger R, Zheng J, Hess DC, **Fagan SC**, Hill WD*. SDF-1 expression is briefly upregulated following hypoxic-ischemic injury in neonates. American Stroke Association, 29th Annual International Stroke Conference, San Diego, CA, Feb., 2004
52. Dahlberg SA, Xu L, Hess DC, Hohnadel E, Hill WD, **Fagan SC***. Erythropoietin and Erythropoietin mimetic peptide in focal cerebral ischemia. American Stroke Association, 29th Annual International Stroke Conference, San Diego, CA, Feb., 2004

53. Hess DC*, Xu L, **Fagan SC**, Edwards DJ, Jones V, Hill WD, Borlongan C, Feuerstein G. Extending the therapeutic window of minocycline in experimental stroke: Translation to human stroke patients. American Stroke Association, 29th Annual International Stroke Conference, San Diego, CA, Feb., 2004
54. **Fagan SC**, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, Ergul A*, Hess DC: Hypertension after experimental stroke: Candesartan provides neurovascular protection. American Heart Association, 59th Annual Fall Conferences and Scientific Sessions of the Council for High Blood Pressure Research. Washington DC, September, 2005
55. Machado LS*, Kozak A, Ergul A, Borlongan CV, Hess DC, **Fagan SC**. Minocycline Inhibits MMPs 2 And 9 And May Represent A Potential Therapeutic Strategy After Acute Ischemic Stroke, Georgia Life Sciences Summit, Atlanta, GA, October 2005
56. Knight RA*, **Fagan SC**, Whitton PA, Ewing JR, Fenstermacher JD, Nagaraja TN. Thrombolytic treatment of acute ischemic stroke in the rat delays early T1sat increases relative to vehicle treatment. Society for Magnetic Resonance in Medicine, November, 2005
57. Elewa HF*, Kozak A, Johnson MH, Ergul A, **Fagan SC**. Controlled blood pressure lowering after experimental cerebral ischemia provides neurovascular protection. American Heart Association, 60th Annual Fall Conferences and Scientific Sessions of the Council for High Blood Pressure Research. San Antonio, TX, October, 2006
58. Ergul, A., Kozak A, Sachidanandam K, Harris AK, **Fagan SC**. Increased intracerebral hemorrhage and altered infarct size and localization after experimental stroke in Type 2 diabetes. 66th Annual Meeting of American Diabetes Association, June 9-13, Washington D.C., 2006.
59. Kaufman SE*, **Fagan SC**, Rychly DJ, Carswell JL. Evaluation of nicardipine usage in post-stroke hypertension. American Society of Health-System Pharmacy Midyear Clinical Meeting, Anaheim CA, December, 2006 (student poster)
60. Machado LS*, Kozak A, Elewa HF, Ergul A, **Fagan SC**. Delayed minocycline is an inhibitor of MMPs activated by stroke: Implications for neurovascular protection. American College of Clinical Pharmacy Spring Practice and Research Forum, Memphis, TN, April, 2007
61. Rychly DJ, Kozak A, Ergul A, Machado LS, Elewa HF, **Fagan SC**. Early remodeling is associated with functional improvement after acute candesartan treatment in stroke. American College of Clinical Pharmacy Spring Practice and Research Forum, Memphis, TN, April, 2007 (Finalist, Best Poster Competition)
62. Carswell JL*, Kauffman SE, Hall C, Rychly DJ, Williams JE, **Fagan SC**. Comparing the Efficacy and Tolerability of Labetalol and Nicardipine in Stroke Patients. American College

of Clinical Pharmacy Spring Practice and Research Forum, Memphis, TN, April, 2007

63. Elewa HF*, Kozak A, Rychly DJ, Ergul A, Frye R, El-Remessy AB, **Fagan SC**. Atorvastatin reduces intracerebral hemorrhage after experimental stroke, Oral Presentation at AHA Scientific Sessions, Orlando, FL, Nov., 2007

64. Gross AK*, Carswell JL, Hess DC, Switzer JA, **Fagan SC**. Evaluation of secondary prevention prescribing in a Joint Commission – certified Primary Stroke Center. American Society of Health System Pharmacists – MidYear Clinical Meeting, Las Vegas, NV, Dec., 2007 (student poster)

65. Li W*, Elgebaly M, Kozak A, **Fagan S**, Dorrance A, Ergul A. (2008) Effect of Permanent vs. Temporary Ischemia Injury on Stroke Outcome in Type 2 Diabetes: Role of Reperfusion on Hemorrhagic Transformation. International Stroke Conference, 2008, New Orleans, LA

66. Li W*, Kozak A, Mezzetti EM, **Fagan SC**, Ergul A. (2008) Chronic hyperglycemia promotes smaller infarct size after experimental stroke. 62th Annual High Blood Pressure Research Conference. Sep 17-20, Atlanta, GA.

67. Johnson CZ*, Wiley DC, El-Remessy AB, Machado LS, AbdelSaid M, Elewa HF, **Fagan SC**. Exploring the beneficial effects of candesartan in stroke. American Society of Health System Pharmacists – MidYear Clinical Meeting, Orlando FL, Dec., 2008 (student poster)

68. Kozak W, Kozak A,* Johnson MH, Elewa HF, **Fagan SC**. U-shaped response to blood pressure lowering in spontaneously hypertensive rats treated with candesartan after experimental stroke. Presented at the XVII European Stroke Conference, Nice, France, May, 2008

69. Kozak A,* Ergul A, El-Remessy AB, Johnson MH, Machado LS, Elewa HF, Wiley DC, Abdel Saiid M, **Fagan SC**. Candesartan augments ischemia-induced proangiogenic state and results in long-term improvement after stroke. International Stroke Conference, San Diego, CA, February, 2009

70. Guan W*, Willis LM, Kozak A, **Fagan SC**. Drug “Rediscovery” for drug development in stroke. Center for Drug Discovery Conference, Athens, GA, November, 2009

71. Wrotek S*, Kozak A, Guan W, **Fagan SC**. Vascular protection with candesartan in experimental ischemic stroke: Influence of reperfusion. Center for Drug Discovery Conference, Athens, GA, November, 2009

72. Elson CL*, Rucker JL, Switzer JA, Hess DC, **Fagan SC**. Evaluation of the safety of blood pressure lowering during the acute stroke period: a follow-up study. American Society of Health System Pharmacists – MidYear Clinical Meeting, Las Vegas, NV, Dec., 2009

(student poster)

73. Cribb J, Boyd M, Bishburg K, Elson CL*, **Fagan SC**. Reintroduction of intravenous minocycline: Suitability of a concentrated solution. American Society of Health System Pharmacists – MidYear Clinical Meeting, Las Vegas, NV, Dec., 2009 (student poster)

74. Prakash R*, Elgebaly MM, Ogbi S, Kelly-Cobbs A, Li W, **Fagan SC**, Ergul A. Vascular protection in diabetic stroke: Role of matrix metalloprotease-dependent vascular remodeling. International Stroke Conference, San Antonio, TX, February, 2010

75. Hess DC*, **Fagan S**, Nichols FT, Pettigrew LC, Fowler A, Clark W, Dolan M, Hall C, Switzer J, Park MA, Close B, Vaishnav A, Dobbs M, Lindsay K, Lutsep H, Ergul A, Bruno A, Edwards DJ, Waller J. Minocycline to Improve Neurologic Outcomes (MINOS) Early Phase Clinical Trial. International Stroke Conference, San Antonio, TX, February, 2010

76. May, JR*, **Fagan SC**. Development of electives that are efficient for faculty and educational for students. American Association of Colleges of Pharmacy, Seattle, WA, June, 2010

77. Li W*, Nagaraja TN, Knight RA, **Fagan SC**, Ergul A. Type 2 diabetes blunts the neurovascular coupling and cerebral blood flow: Relevance to ischemic injury. International Stroke Conference, Los Angeles, CA, February, 2011

78. Switzer JA*, Hess DC, Waller JL, Ergul A, Portik-Dobos V, Machado LS, **Fagan SC**. Lower levels of blood biomarkers in acute ischemic stroke patients treated with IV minocycline. International Stroke Conference, Los Angeles, CA, February, 2011

79. Prakash R*, Ogbi S, Stern JE, El-Remessy A, **Fagan SC**, Ergul A. Diabetes stimulates brain angiogenesis: In vitro and in vivo evidence. International Stroke Conference, Los Angeles, CA, February, 2011

80. Veenstra DL, **Fagan SC**, Guzauskas GF, Boudreau D, Villa KF*. Cost-effectiveness of tPA for acute ischemic stroke (AIS) patients treated within 4.5 hours of symptom onset. Quality of Care and Outcomes in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC, May, 2011

81. Phillips BG,* **Fagan SC**, Brooks P, Buck B, Francisco GE. Clinical and translational science: PharmD to PhD and beyond. 2011 AACP Annual Meeting, San Antonio, TX, July, 2011

82. Cronic L*, Soliman S, El-Remessy AB, **Fagan SC**. Angiogenic and vasculoprotective potential of angiotensin receptor antagonists in the brain. 2011 ACCP Annual Meeting, Pittsburgh, PA, October, 2011 * - WINNER Best student poster (out of 94)

83. Alhusban A*, Kozak A, **Fagan SC**. Vascular protection with candesartan: Beyond blood pressure lowering. 2011 ACCP Annual Meeting, Pittsburgh, PA, October, 2011* RUNNER UP, Best Resident/Fellow poster
84. Cribb AH*, Houg DK, Rocker JL, Switzer JA, Hess DC, **Fagan SC**. Safety associated with body temperature regulation during the acute stroke period at a primary stroke center. 2011 ACCP Annual Meeting, Pittsburgh, PA, October, 2011, Student poster
85. Prakash R*, El-Remessy AB, Somanath PR, **Fagan SC**, Ergul A. VEGF and peroxynitrite interplay regulates cerebral angiogenic mediators in diabetes. International Stroke Conference 2012, New Orleans, LA, February, 2012
86. Switzer JA*, DeSousa K, Mohorn P, Waller JL, **Fagan SC**, Hughes D, Bruno A, Nichols FT, Hess DC, Rocker JL. Incomplete reversal of anticoagulation following intracranial hemorrhage with three-factor prothrombin complex concentrate. International Stroke Conference 2012, New Orleans, LA, February, 2012
87. Prakash R*, Stern JE, El-Remessy AB, **Fagan SC**, Johnson MH, Dore-Duffy P, Ergul A. Cerebrovascular remodeling in diabetes: relevance to stroke. International Stroke Conference 2012, New Orleans, LA, February, 2012
88. Li W, Portik-Dobos V, Chung C, Prakash R, Johnson MH, **Fagan SC**, Ergul A. Acute metformin treatment worsens short-term stroke outcome: Comparison of underlying mechanisms in control and type 2 diabetic rats. International Stroke Conference 2012, New Orleans, LA, February, 2012
89. Soliman S*, El-Remessy AB, Cronic LE, Somanath PR, Ergul A, **Fagan SC**. Vascular Protection Mediates Neuroprotection: Role of VEGF-A and B. International Stroke Conference 2012, New Orleans, LA, February, 2012
90. Ishrat T*, Pillai B, Ergul A, **Fagan SC**. Candesartan increases metalloproteinase activation but still provides benefit when in combination with tissue plasminogen activator in experimental embolic stroke. International Stroke Conference 2013, Honolulu, HI, February, 2013
91. Kelly-Cobbs AI*, Li W, Prakash R, Pillai B, Oghi SN, Coucha M, Johnson M, **Fagan SC**, Ergul A. Targets of vascular protection in acute ischemic stroke differ in Type 2 Diabetes. International Stroke Conference 2013, Honolulu, HI, February, 2013
92. Coucha M*, Li W, **Fagan SC**, Ergul A. Protein nitration impairs myogenic reactivity of cerebral vessels in both ischemic and non-ischemic hemispheres. International Stroke Conference 2013, Honolulu, HI, February, 2013
93. Prakash R*, Li W, Qu Z, **Fagan SC**, Ergul A. Diabetes impairs post-stroke

cerebrovascular plasticity and long-term functional recovery. International Stroke Conference 2013, Honolulu, HI, February, 2013

94. Alhusban A, Fouda A*, Pillai B, Ergul A, **Fagan SC**. BDNF knockdown abrogates AT1 blockade-induced improvement in stroke outcome. International Stroke Conference 2014, San Diego, CA, February, 2014

95. Qu Z, Li W, Prakash R, **Fagan SC**, Ergul A*. Diet-induced diabetes impairs neovascularization and functional recovery after ischemic stroke. International Stroke Conference 2014, San Diego, CA, February, 2014

96. Ishrat T*, El-Remessy AB, Pillai B, Soliman S, Ergul A, **Fagan SC**. Thioredoxin interacting protein: A novel target for neuroprotection in experimental thromboembolic stroke in mice. International Stroke Conference 2014, San Diego, CA, February, 2014

97. Hoda MN*, Khan M, Wakade C, Ergul A, **Fagan SC**, Hess DC. Remote ischemic conditioning (RIC), a combined regimen of Pre- and Post- conditionings (RIPerC and RIPostC), provides long-term motor and cognitive benefits in murine embolic stroke model (eMCAO). International Stroke Conference 2014, San Diego, CA, February, 2014

98. Coucha M*, Li W, Abdelsaid M, Hafez S, **Fagan SC**, Ergul A. SOD overexpression accounts for the neurovascular protection in rats following ischemic stroke. International Stroke Conference 2014, San Diego, CA, February, 2014

99. Li W*, Ma H, Prakash R, **Fagan SC**, Ergul A. The impact of method of ischemia/reperfusion injury on stroke outcome in type 2 diabetes. International Stroke Conference 2014, San Diego, CA, February, 2014

100. Hafez S*, Abdelsaid M, Coucha M, **Fagan SC**, Ergul A. Matrix metalloproteinase 3 (MMP3) exacerbates the hemorrhagic transformation in hyperglycemic stroke. International Stroke Conference 2014, San Diego, CA, February, 2014

101. Soliman S*, Ishrat T, Patel A, Fouda A, Ergul A, **Fagan SC**. Sequential treatment with minocycline and candesartan improves long term recovery after stroke. International Stroke Conference 2014, San Diego, CA, February, 2014

102. Boudreau DM*, Guzauskas GF, Tayama D, **Fagan SC**, Veenstra DL. An updated cost-effectiveness analysis of rtPA for acute ischemic stroke treated within 3 hours of symptom onset. International Stroke Conference 2014, San Diego, CA, February, 2014

103. Abdelsaid M*, Prakash R, Li W, Coucha M, **Fagan SC**, Ergul A. The role of ischemia/reperfusion generated nitrate stress on VEGF angiogenic signaling in diabetic rats. International Stroke Conference 2014, San Diego, CA, February, 2014

104. Boudreau DM*, Guzauskas GF, Lalla D, Tayama D, **Fagan SC**, Veenstra DL. An updated cost-effectiveness analysis of r-tPA for acute ischemic stroke treated within 3 hours of symptom onset. American Academy of Neurology, Philadelphia, PA, April 26- May 4, 2014.
105. Fouda AY*, Hardigan T, Soliman S, Pillai B, Ergul A, **Fagan SC**. Enhancement of cerebrovascular relaxation by angiotensin receptor Type 2 agonist, Compound 21, is lost in Type 2 diabetes. High Blood Pressure Council of AHA, San Francisco, CA, September 10–13, 2014
106. Valenzuela JP*, Qu Z, Li W, El-Remessy A, Mohamed I, **Fagan SC**, Ergul A. High fat and high glucose synergistically impair brain microvascular endothelial cell survival and angiogenic potential after hypoxia. International Stroke Conference 2015, Nashville, TN, February, 2015
107. Hafez S,* Hoda MN, Guo X, **Fagan SC**, Ergul A. Low dose tissue plasminogen activator (tPA) amplifies vascular injury and worsens functional outcomes in acute hyperglycemic stroke independent of the model of reperfusion. International Stroke Conference 2015, Nashville, TN, February, 2015
108. Valenzuela JP*, Zhi Q, Li W, Ward R, Prakash R, **Fagan SC**, Ergul A. High fat diet-induced metabolic syndrome alters cerebrovascular architecture: Relevance to cognitive deficits and stroke outcomes. International Stroke Conference 2015, Nashville, TN, February, 2015
109. Hafez S,* El-Shafey S, **Fagan SC**, Ergul A. Inhibition of matrix metalloprotease 3 reduces vascular injury and improves functional outcomes in hyperglycemic stroke. International Stroke Conference 2015, Nashville, TN, February, 2015
110. Vaibhav K,* Khan MI, Baban B, Ahmed H, Wang P, Chaudhary A, **Fagan SC**, Hess DC, Dhandapani KM. Remote ischemic conditioning (RIC) after intracerebral hemorrhage regulates macrophage polarization and CD36 expression to promote hematoma resolution. International Stroke Conference 2015, Nashville, TN, February, 2015
111. Fouda AY,* Soliman S, Kozak A, Pillai B, Ergul A, **Fagan SC**. Impaired response to post-stroke candesartan treatment in a model of type 2 diabetes: Relationship to angiotensin receptors expression. International Stroke Conference 2015, Nashville, TN, February, 2015
112. Ishrat T, Pillai B, Somanath PR, Ergul A, **Fagan SC**. Early AT1 blockade ameliorates ischemia/reperfusion injury by PI3K/Akt and eNOS pathways: in vivo and in vitro evidence. International Stroke Conference 2015, Nashville, TN, February, 2015
113. Soliman S, Ishrat T,* Pillai B, Ergul A, Fagan SC. Silencing VEGF-B diminishes the

neuroprotective effect of candesartan treatment after experimental focal cerebral ischemia. International Stroke Conference 2015, Nashville, TN, February, 2015

114. Ishrat T*, Fouda AY, Pillai B, Eldahshan W, Ahmed HA, Waller JL, Ergul A, **Fagan SC**. Dose-response and therapeutic time-window of Compound 21: A randomized preclinical trial in a rat model of thromboembolic stroke. International Stroke Conference 2016, Los Angeles, CA, February, 2016

115. Fouda AY*, Ishrat T, Ahmed H, Pillai B, Artham S, Ergul A, **Fagan SC**. Involvement of the contralesional angiotensin Type 2 receptor in Compound 21 mediated functional recovery after stroke. International Stroke Conference 2016, Los Angeles, CA, February, 2016

116. Hafez S*, Abdelsaid M, Elshafey S, **Fagan SC**, Ergul A. Focal knockdown of matrix metalloprotease 3 reduces hemorrhagic transformation and improves neurobehavioral outcomes in hyperglycemic stroke. International Stroke Conference 2016, Los Angeles, CA, February, 2016

117. Li W*, Valenzuela JP, El-Shafey S, Ward R, Guo X, **Fagan SC**, Ergul A. Human dose tPA improves functional outcomes in both sexes in embolic model of stroke: Differential effect on hemorrhagic transformation. International Stroke Conference 2016, Los Angeles, CA, February, 2016

118. Valenzuela JP*, Li W, Abdul Y, Ward R, El-Shafey S, Guo X, **Fagan SC**, Ergul A. Diabetes amplifies vascular injury and worsens stroke outcome in young female rats: Loss of protection. International Stroke Conference 2016, Los Angeles, CA, February, 2016

119. Hafez S*, Abdelsaid M, **Fagan SC**, Ergul A. Hyperglycemia mediates matrix metalloprotease 3 activation through tyrosine nitration after stroke. International Stroke Conference 2016, Los Angeles, CA, February, 2016

120. Ishrat T*, Pillai B, Fouda AY, Eldahshan W, Ahmed H, Noguchi K, **Fagan SC**. DS-1040, a novel, selective thrombin-activatable fibrinolysis inhibitor does not increase hemorrhagic risk in a mechanical model of stroke in rats. Society for Neuroscience Annual Meeting, San Diego, CA, November, 2016

121. Fouda AY, Newsome AS,* Switzer JA, Hafez S, Ergul A, Edwards DJ, Hess DC, Nichols F, Bruno A, Zhi W, **Fagan SC**. Pharmacokinetics of minocycline in critically ill patients with intracerebral hemorrhage. 46th Society for Critical Care Medicine Critical Care Congress, Honolulu, Hawaii, January, 2017 (selected for Research Snapshot oral presentation)

122. Li W, Valenzuela JP*, Dong G, Ward R, **Fagan SC**, Ergul A. Low dose tPA worsens the short term outcome after thromboembolic stroke in both male and female diabetic

animals. International Stroke Conference, Houston, TX, February, 2017.

123. Li W*, Valenzuela JP, Dong G, Abdul Y, Ward R, **Fagan SC**, Ergul A. Deferoxamine treatment improves outcomes after embolic stroke in diabetic rats. International Stroke Conference, Houston, TX, February, 2017

124. Li W*, Hafez S, Valenzuela JP, Ward R, Dong G, El-Shafey S, **Fagan SC**, Ergul A. Diabetes impairs long-term functional recovery in an embolic model of stroke in a sex independent manner. International Stroke Conference, Houston, TX, February, 2017

125. Ahmed HA*, Ishrat T, Pillai B, Bunting K, Vazdarjanova A, Waller JL, **Fagan SC**. Angiotensin receptor (AT2R) agonist C21 accelerates cognitive functional recovery after permanent stroke in aged animals. International Stroke Conference, Los Angeles, CA, January, 2018

126. Ahmed HA*, Ishrat T, Pillai B, Fouda AY, Sayed MA, Waller JL, Ergul A, **Fagan SC**. Delayed therapeutic window for prevention of progressive cognitive impairment after experimental stroke. International Stroke Conference, Los Angeles, CA, January, 2018

127. Eldahshan W*, Pillai B, Sayed M, Ishrat T, Ergul A, **Fagan SC**. Angiotensin Type 2 receptor stimulation with Compound 21 improves stroke outcome in female rats: possible role for peroxisome proliferator-activated receptor gamma. International Stroke Conference, Los Angeles, CA, January, 2018

128. Li W*, Dong G, Menk PT, Abdul Y, Ward R, **Fagan SC**, Ergul A. Deferoxamine improves vascular repair and cognitive outcomes after embolic stroke in diabetic but not control animals: Interaction with tPA. International Stroke Conference, Los Angeles, CA, January, 2018

129. Li W*, Dong G, Menk P, Abdul Y, Ward R, **Fagan SC**, Ergul A. Differential effects of deferoxamine treatment on neurologic deficits in young diabetic female animals after embolic stroke. International Stroke Conference, Los Angeles, CA, January, 2018

* - presenting author

Book Chapters

1. **Fagan SC** : Stroke in Pharmacotherapy Self Assessment Program, Module 3 Neurology and Psychiatry, June, 1992

2. **Fagan SC**: Management of hypertension in stroke. in Primer on Cerebrovascular Diseases, Welch KMA, Caplan L, Reis D, Seisjo B, Weir B, eds., Academic Press, San Diego,CA, 1997

3. O'Sullivan TL and **Fagan SC**: Drug-induced Communication Disorders in Medical Speech-Language Pathology: A Practitioner's Guide, Johnson A and Jacobson B, eds., Thieme, New York, NY, 1997
4. **Fagan SC**, Chant C: Thrombolysis and acute ischemic stroke: Pharmacotherapy Self-Assessment Program III; American College of Clinical Pharmacy, 1998
5. **Fagan SC**, Welch KMA: Evaluation of Neurologic Function. in Pharmacotherapy: A pathophysiologic approach. (4th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, Appleton and Lange, Stamford, CT , 1999
6. **Fagan SC**, Kwiatkowski T, Lyden PD: Further analysis of the NINDS Study in Thrombolytic Therapy for Stroke., Lyden PD, editor, The Humana Press Inc., Totowa, NJ, 2001
7. **Fagan SC**, Nichols FT: Evaluation of Neurologic Function. in Pharmacotherapy: A pathophysiologic approach. (5th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY , 2002
8. Bradberry JC, **Fagan SC**: Stroke in Pharmacotherapy: A pathophysiologic approach. (5th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY ,2002
9. **Fagan SC**, Ryan M: Neurology Specialty Pharmacy Practice in Encyclopedia of Clinical Pharmacy, DiPiro JT, ed., Marcel Dekker, Inc., New York, NY, 2002
10. **Fagan SC**, Hess DC: Stroke in Pharmacotherapy: A pathophysiologic approach. (6th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY ,2005
11. **Fagan SC**, Nichols FT: Evaluation of Neurologic Function. in Pharmacotherapy: A pathophysiologic approach. (6th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY, 2005
12. **Fagan SC**, Kwiatkowski T, Lyden PD: Further analysis of the NINDS Study; Long-term outcome, subgroups and cost effectiveness. in Thrombolytic Therapy for Stroke. Second Edition, Lyden PD, editor, The Humana Press Inc., Totowa, NJ, 2005
13. **Fagan SC**, Mehta S: Stroke and TIA in Primary Care Pharmacotherapy. Linn WD, ed, McGraw-Hill, New York, NY, 2007
14. **Fagan SC**, Hess DC: Stroke in Pharmacotherapy: A pathophysiologic approach. (7th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY ,2007

15. **Fagan SC**, Nichols FT: Evaluation of Neurologic Function. in Pharmacotherapy: A pathophysiologic approach. (7th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY, 2007
16. **Fagan SC**, Hess DC: Stroke in Pharmacotherapy: A pathophysiologic approach. (8th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY, 2011
17. **Fagan SC**, Nichols FT: Evaluation of Neurologic Function. in Pharmacotherapy: A pathophysiologic approach. (8th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY, 2011
18. Deremer DL, Manasco KB, **Fagan SC**. Research – You are a scholar. in Residency Survival Guide. American College of Clinical Pharmacy, Lanexa, KS, 2011
19. **Fagan SC**, Hess DC: Stroke in Pharmacotherapy: A pathophysiologic approach. (9th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY, 2014
20. **Fagan SC**, Alhusban A, Nichols FT: Evaluation of Neurologic Function. in Pharmacotherapy: A pathophysiologic approach. (9th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY, 2014
21. Switzer JA, Sikora A, Hess DC, **Fagan SC**: Minocycline for Acute Cerebral Hemorrhage in Rational Basis for Translation in Stroke Therapy. Frontiers in Neurotherapeutics, Micieli and Amantea, Editors; CRC Press, Taylor and Francis Group, Boca Raton, FL, August, 2014
22. **Fagan SC**, Hess DC: Stroke in Pharmacotherapy: A pathophysiologic approach. (10th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY, 2017
23. Ryan M, Ryan SJ, **Fagan SC** . Evaluation of Neurologic Function. in Pharmacotherapy: A pathophysiologic approach. (10th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY, 2017
24. Ergul, A. and **Fagan, S.C**. Risk Factors: Diabetes in A Primer on Cerebrovascular Diseases, Second Edition, editors: Caplan LR, Biller J, Leary M, Thomas A, Lo E, Yenari M, and Zhang J, Elsevier/Academic Press, 2017

Educational Materials

1. Fagan SC, Miller DA : Clinical Pharmacy Training - The Case Presentation. A 15-minute video designed to be used in the experiential components of baccalaureate and doctor of pharmacy programs. Distributed throughout U.S.A. and CANADA, 1989
2. Smythe MA, Fagan SC : Clinical Pharmacy Training - The Case Discussion. A 29-minute video designed to be used in the experiential training of pharmacy students. It is a follow-up to the previously developed video.1991
3. BMS-Sanofi Partnership: One stroke is more than enough. A continuing education video offering for long-term care nurses, focusing on secondary stroke prevention (Faculty).

Grants and Contracts Funded

1. A randomized, 21-day, double-blind, parallel group, multicenter study to compare the efficacy and safety of nimodipine with that of placebo in patients with acute ischemic stroke. G.H. Besselaar Associates. Co-Investigator (with Dr. KMA Welch) \$77,100 4/87 - 12/89
2. Effect of antihypertensive agents on cerebral blood flow in the elderly. Fund for Henry Ford Hospital. Principal Investigator. \$5,000 7/87 - 7/89
3. Effect of Nimodipine on cerebral blood flow in acute ischemic stroke. Fund for Henry Ford Hospital. Principal Investigator. \$4,500 12/87 - 12/89
4. Clinical Pharmacy Training Film Grant. Merck Foundation. Principal Author and Producer. \$3,960 1/88 - 12/89
5. An indicator dilution technique for measurement of cerebral blood flow. Project 1 of the Center for Stroke Research. U.S. Public Health Service - National Institute of Neurologic Disorders and Stroke. Subproject Co-Investigator. (with J.R. Ewing, M.S.) \$574,130 4/1/89 - 3/31/94 (18% salary reimbursement)
6. Cerebral blood flow using FC-23 NMR in cats. Fund for Henry Ford Hospital. \$2,100 Principal Investigator 7/89 - 12/90
7. Cerebral blood flow response to antihypertensive therapy with enalapril. MEAD JOHNSON CNS AWARD OF AMERICAN COLLEGE OF CLINICAL PHARMACY. \$10,000 Principal Investigator 7/90 - 6/91
8. Phase II-B randomized controlled study of tissue plasminogen activator for acute ischemic stroke - Coordinating Center. U.S. Public Health Service. National Institute of Neurologic Disorders and Stroke. \$1,095,000.00 Co-Investigator (with Barbara C. Tilley, Ph.D.) 6/11/90 - 7/93 (15% salary reimbursement)
9. Drug distribution contract for the NINDS TPA STROKE TRIAL. Genentech, Inc. \$191,400 CoInvestigator (with Barbara C. Tilley, Ph.D.) 12/90 - 7/93 (10% salary reimbursement)

10. Clinical Pharmacy Training Film Grant. Sandoz \$4,300.00
Co-Principal Investigator (with Maureen A. Smythe, Pharm.D.) 12/90 - 1/92
11. Double-blind, placebo-controlled pilot study evaluating safety and tolerability of two intravenous bolus doses of CGS-19755 in the treatment of patients with acute ischemic stroke. Ciba-Geigy, \$72,000 Co-Principal Investigator (with Steven R. Levine, M.D.) 2/91 - 1/92
12. Assessment of the efficacy of minocycline in the treatment of rheumatoid arthritis. U.S. Public Health Service, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Coordinating Center Consultant - 10% salary reimbursement. 6/91-6/93
13. Cerebral blood flow response to ramipril. Hoescht-Roussel, PI, \$25,000. 1/91-1/94
14. Cerebral blood flow response to enalapril. American Heart Association - Michigan Affiliate, PI, \$25,500. 7/92-7/93
15. Clinical Pharmacy Training - The Pharmacy and Therapeutics Committee. (video), CI (with M.A. Smythe), Sandoz, Inc. \$6,000. 7/92-7/93
16. Phase II-B randomized controlled study of tissue plasminogen activator for acute ischemic stroke - Coordinating Center. U.S. Public Health Service. National Institute of Neurologic Disorders and Stroke. \$1,095,000.00 CoInvestigator (with Barbara C. Tilley, Ph.D.) 7/93 - 1/99 (5% salary reimbursement)
16. Gustavus A. Pfeiffer Faculty Development Research Fellowship - 1993-1994. American Foundation for Pharmaceutical Education \$17,500; Awarded 4/93
17. Career Development Chair Award - 1993-1994. Wayne State University \$18,500; Awarded 4/93
18. Outcomes/ Pharmacoeconomics Fellowship - PI, Bristol Myers Squibb, Inc. \$64,000 - 1/95
19. "Intracerebral hemorrhage formation and TPA in ischemic stroke"; ACCP - CNS Research Award: 6/95 - 7/96 - PI, \$10,000
20. " Establishing the effect of neuroprotection on hemorrhagic transformation after acute ischemic stroke"; Wayne State University Undergraduate Research Award - 1997; \$500.00 (with Sharon Ulep)
21. "Burden of illness associated with atopic dermatitis"; Pharmacon International; 10/97 - 10/98, PI, \$66,000

22. " NMR studies of hemorrhagic transformation in ischemic stroke " : PHS: NINDS; 4/99 - 4/03; Co - Investigator (R. Knight, Ph.D., PI); \$939,089 (20% salary reimbursement)
23. "Effect of early methylprednisolone on the development of hemorrhage after cerebral ischemia": MCG-UGA Inter-Institutional Grants Program; 7/1/2000 – 6/30/2001, PI, \$52,630
24. "Maxipost 52-week pharmacoeconomic evaluation"; Bristol-Myers Squibb; 9/15/2000 – 9/15/2001, PI, \$48,463
25. "POST outcomes evaluation – Long Term Study", Bristol-Myers Squibb; 1/18/2001 – 1/18/2002; PI; \$56, 494
26. "POST outcomes evaluation – Prospective Study", Bristol-Myers Squibb; 1/18/2001 – 1/18/2001; PI; \$58, 042
27. "Student Scholarships in Cerebrovascular Disease", American Stroke Association; 5/01 – 8/01; Preceptor (Alexis Simpkins and Chris Jacobs); \$4,000
28. "CINAPS – Neuroprotection Drug Review", PHS- NINDS (subcontract from MUSC, Tilley, PI); 1/1/2002 – 7/31/2002; \$19,847 (20% salary x 1.5 months; 5% x 4.5 months)
29. "Vascular protection in acute ischemic stroke", PHS-NINDS RO1NS044216-01(PI); 5/1/2003 – 4/30/2006; \$614,700 (20% salary)
30. "CINAPS – Neuroprotection Drug Review", PHS- NINDS (subcontract from MUSC, Tilley, PI); 8/1/2002 – 7/31/2006; \$108, 181 (8.77% salary)
31. "Blood pressure and vascular protection after acute stroke", Grant-in-Aid, American Heart Association Southeast Affiliate; 7/1/2003 – 6/30/2005; \$154,000 (10% salary)
32. . "Student Scholarship in Cerebrovascular Disease", American Stroke Association; 5/03 – 8/03; Preceptor (Sylvia Annette Dahlberg); \$2,000
33. "Neuroprotective agents for clinical trials in ALS: A systematic assessment", Amyotrophic Lateral Sclerosis Association; 9/04 – 6/05; PI; \$5,200
34. "Vascular protection with atorvastatin after ischemic stroke in diabetes", Pfizer, Inc; 8/06 - 9/08; PI; \$62,450
35. "Mechanisms and consequences of hypertension after stroke", VA Merit Review; 10/06 – 10/10; PI; \$521,000
36. "Neuroprotective Exploratory Trials in Parkinsons Disease - LS-1", PHS- NINDS (subcontract from MUSC, Tilley, PI); 8/1/2006 – 7/31/2011; Pharmacology consultant (5% salary)

37. "Glucose Regulation in Acute Stroke Patients (GRASP)", PHS- NINDS (MCG, Christiana Hall, MD, PI); Consultant (\$24,000 over 3 years)
38. "The Effects of Improved Hospital Reimbursement on RT-PA Use", Centers for Disease Control and Prevention (Dawn Kleindorfer, MD, University of Cincinnati, PI); 1/1/2007 – 12/31/2010; Consultant (No funds)
39. "Vascular protection with atorvastatin after ischemic stroke in diabetes", Investigator-initiated grant supplement; Pfizer, Inc; 10/2007 – 12/2009; PI; \$46,310
40. "Minocycline to Improve Neurologic Outcome (MINO)", RO1 NS055728-01A1 (subcontract from MCG; PI:Hess); PHS-NINDS; PI on subcontract; 1/4/2007-3/31/2010; \$200,688
41. "Angiotensin blockade to promote early vascular remodeling and recovery after ischemic stroke", American Legion – Department of Georgia; 7/1/2008 – 6/30/2009; PI; \$17,000
42. "Mechanisms of Vascular Protection after Stroke"; RO1 NS063965-01A1; PHS-NINDS; PI; 7/15/2009 – 2/28/2014; \$1,488,681; no cost extension until 2/28/2016
43. "Mechanisms and Consequences of Hypertension after Stroke; VA Merit Review: BX000891; PI; 4/1/2011 – 9/30/2014
44. "Minocycline in Acute Cerebral Hemorrhage"; American Heart Association Clinical Research Program; CRP14510026; co-I; 1/1/2013 – 12/30/2014 (subcontractor)
45. "Vascular injury and recovery in diabetic ischemic stroke"; RO1NS083559; PHS-NINDS; Co-I (subcontract from GRU – Ergul, PI); 2/1/2014 – 1/31/2019
46. "Angiotensin agonism to promote recovery after stroke"; R21NS088016; PHS-NINDS; PI; 7/1/2014 – 6/30/2016 : \$650,000: NCE to 6/30/2018
47. "Assessment of Compound DS in an experimental model of hemorrhagic transformation of ischemic stroke"; Daiichi Sankyo, Inc (Japan) to Augusta Biomedical Research Corporation (Fagan, PI); 8/1/2014 – 7/31/2015: \$134,500
48. "Progressive post-stroke cognitive impairment: Mechanisms and Intervention", R01NS104573; PI (MPI with Ergul, MUSC); 10/1/2018 – 9/30/2023; UGA consortium: \$735,000.00

Current projects/ interests :

- Angiogenesis as a target for recovery in ischemic stroke
- vascular protection after acute ischemic stroke
- neuroprotection and vascular restoration for acute ischemic stroke
- stroke outcomes
- Post stroke cognitive impairment